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ABSTRACT
Galectin-1: Development of a Novel Protein Therapy for LGMD2B
Mary Lorena Vallecillo Munguía
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Muscular dystrophies are a heterogeneous group of genetic diseases that involve
mutations in genes leading to progressive muscular weakness. Limb-Girdle Muscular Dystrophy
2B (LGMD2B) is a subset of muscular dystrophy caused by mutations in the DYSF gene, which
encodes for dysferlin protein and has an incidence of 1/100,000-1/200,000 people, or 1/300
people of Libyan Jewish descent. Since there is no effective treatment that can cure or reverse
effects of LGMD2B once diagnosed, our goal is to investigate and develop a protein therapy that
mitigates effects of this disease in patients. Galectin-1 (Gal-1) is a small, soluble 14.5 kDa
protein with a carbohydrate recognition domain capable of stabilizing the sarcolemma. The exact
role that Gal-1 plays in myogenic cells is not fully understood, however, it is known that Gal-1
possesses anti-inflammatory properties and increases the terminal differentiation of committed
myogenic cells. Our hypothesis is that Gal-1 treatment increases myogenic potential, improves
membrane repair capability, and modulates the immune response in models of LGMD2B by
stabilizing muscle integrity, leading to decreased disease manifestation. To test this hypothesis
and assess the effect of Gal-1 treatment on myogenesis, anti-inflammatory modulation, and
membrane repair, we designed, produced, and purified recombinant human galectin-1 (rHsGal-1)
to be used in LGMD2B models. Our in vitro results indicate that after 2-3 days of treatment with
0.11µM rHsGal-1, A/J-/- myotubes enhance expression of myogenic late markers and increase in
size and alignment. Additionally, after short-term treatment, rHsGal-1 improves membrane
repair capability in a Ca2+ independent manner through an activated carbohydrate recognition
domain (CRD) in in vitro and in vivo models of LGMD2B. We give evidence that rHsGal-1
upregulates anti-inflammatory cytokines, increases functional activity, and modulates the
canonical NF-κB inflammatory pathway in dysferlin-deficient models by decreasing expression
of TAK-1 and the p65 and p50 subunits in vitro and short-term in vivo treatment. Similar effects
of the rHsGal-1 treatment were observed in patient-derived dysferlin-deficient human myotubes.
Exploratory results show a potential decrease in muscle fat deposition in Bla/J mice.
Furthermore, Gal-1 contributes to immune modulation by helping to initiate muscle regeneration
by shifting M2 macrophage polarization. Together, our novel discoveries provide direct evidence
that Gal-1 is a promising candidate to treat LGMD2B disease pathologies by improving
expression of late-stage myogenic markers, improving membrane repair in vitro and short-term
in vivo studies, promoting muscle regeneration through immune modulation, and reducing
canonical NF-κB inflammation.

Keywords: muscular dystrophy, LGMD2B, Galectin-1, membrane repair, NF-κB, inflammation,
macrophage polarization
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CHAPTER 1: INTRODUCTION

Since the 1830s, skeletal muscle disorders have been classified as progressive muscle
weakness due to degeneration and loss of muscle fibers. In many patients, symptoms eventually
result in premature death.1, 2 Scientists have made significant advances trying to understand
pathologies and development of therapies. Despite increased understanding of this group of
diseases, cures for muscular dystrophies are still elusive. This work focuses on developing
Galectin-1 (Gal-1) as a potential protein therapy for use in Limb-Girdle Muscular Dystrophy 2B
(LGMD2B).

1.1

Introduction to Skeletal Muscle
Skeletal, smooth, and striated muscles are the three major tissues in the human body.

Skeletal muscle, composing a third of body mass in healthy individuals plays a critical role in
shape, stance, contractile movement, and voluntary locomotion of the human body.3-5
Development of skeletal muscle begins with a key process known as myogenesis.6 During
myogenesis, mesoderm-derived satellite cells proliferate and become myoblasts. Myoblasts then
differentiate into myocytes which fuse and form multinucleated muscle cells known as
myotubes.7 Mature myotubes continue towards formation of many single muscle fibers bundle
together into myofibrils and myofilaments.
Myogenesis, the formation of skeletal muscle tissue, consists of several distinct phases. This
process is regulated by hierarchical, well-arranged transcriptional factors including paired-box
protein 7 (Pax 7), myoblast determination protein 1 (MyoD), and myogenin (MyoG) and myosin
heavy chain (MHC), expressed during the early, middle, and late stage of myogenesis,
1

respectively.8 MyoD is a marker indicative of cell fusion and muscle differentiation.8, 9 MyoG
and MHC are late markers of myogenesis involved in muscle development and repair and muscle
contraction.10, 11 Since myogenesis is a crucial process for muscle development and regeneration,
inhibition of myogenesis leads to the interruption of muscle differentiation, maturation, and
myofiber formation.

Figure 1.1. Schematic of Muscle Fiber. Skeletal Muscle Fiber surrounded by the sarcolemma containing sarcoplasm
reticulum, and myofibrils. Created by BioRender.com.

Skeletal muscle structure is essential for myofiber survival (Fig. 1.1). A single muscle cell is
made up of hundreds of thousands of fibers bundled together and surrounded by the
sarcolemma.12 Like other cells, muscle cells are fragile structures that need to be protected to
keep homeostasis. A critical component in maintaining muscle cell homeostasis is the
2

sarcolemma. Genetic modification or abnormalities in the sarcolemma can lead to muscular
disorders including, but not limited to, muscular dystrophies.

1.2

Introduction to Muscular Dystrophies
Muscular dystrophy is a heterogeneous group of genetic diseases that cause progressive

weakness and degeneration of the skeletal muscle. Different types of muscular dystrophy affect
specific muscle groups with a varying age of onset. Symptoms vary in first appearance and
severity because of impairment in different genes. People suffering from muscular dystrophies
report clinical features including loss of strength and ambulation, high levels of serum creatine
kinase (CK), chronic inflammation, fat infiltration in muscle fibers, and death.13, 14 The
contractile properties of muscle fibers make them prone to membrane ruptures and other damage.
Under normal conditions, these ruptures are repaired quickly and efficiently. However, in many
muscular dystrophies, damaged fibers are permanently exposed to stress which leads to chronic
degeneration. While there may be no current cure for muscular dystrophies, temporary
treatments can help control symptoms and slow the progression of the disease.

1.2.1

Classification of Muscular Dystrophies
There are eight major forms of muscular dystrophies classified by the main symptoms,

age of onset, and mutation of a specific gene or protein complex as described in Table 1.
Additionally, muscular dystrophies affect a wide range of muscle groups. The location of
affected muscle groups helps to identify patterns and treatment approaches for specific subsets of
muscular dystrophies. Figure 1.2

3

Table 1.1: Classification of Muscular Dystrophies
Type of Muscular Dystrophy

Age of Onset

Protein/Mutation

2 to 6 years

Dystrophin15

Adolescence to early
adulthood
Birth

Dystrophin16

Childhood to early teens

Mutations in several genes18

Childhood to early adults

DUX4/SMCHD119

Myotonic

20 to 40 years

DMPK gene20, 21

Oculopharyngeal

40 to 70 years

Polyadenylate binding
proteinnuclear-122

Late childhood to middle age

Various23

Duchenne
Becker
Congenital
Emery-Dreifuss
Facioscapulohumeral

Limb-Girdle

Merosin17

1.2.1.1 Duchenne Muscular Dystrophy
Duchenne (DMD) is the most common and severe type of muscular dystrophy. This Xlinked disease is caused by non-specific mutations in the dystrophin gene which encodes a 427
kDa protein called dystrophin (Fig 1.2A).24 Dystrophin is the largest gene in the human genome
and is thus prone to common mutations such as insertions and deletions.15 Dystrophin is part of
an associated-glycoprotein complex with several extracellular domains.25 Deficiencies of
dystrophin lead to compromised structural support and integrity of myofibers. Lack of the
dystrophin gene causes muscle weakness, muscle degeneration and necrosis, decreased levels of
antioxidants and other complications such as microtubule disorganization, and respiratory
failure.13, 15 Malfunctioning dystrophin is responsible for impaired regeneration, repair, and
chronic inflammation in DMD muscles. While DMD is the most common type of muscular
dystrophy, still there is no cure for this disease. Currently, several therapeutic approaches

4

including use of steroids, stem cell transplantation, gene therapy, and protein upregulation are in
development.

Figure 1.2. Main Types of Muscular Dystrophies. Red highlighted regions show the specific effected muscular
groups. A. Duchenne and Becker. B. Limb-Girdle. C. Emery-Dreifuss. D. Facioscapulohumeral. E. Myotonic. F.
Oculopharyngeal. Created by BioRender.com.

1.2.1.2 Becker Muscular Dystrophy
Becker Muscular Dystrophy (BMD) is caused by mutations at the Xp21.2 locus of the
dystrophin gene.26, 27 Dystrophin gene codes for the dystrophin protein. This protein is essential
5

in stabilizing and protecting muscle fibers and assists in intracellular chemical signaling.28, 29
This X-linked recessive disease causes progressive weakness and wasting of the cardiac and
skeletal muscles. Muscle weakness becomes apparent between ages 5-15 and is similar in nature
to DMD. However, symptoms have a later age of onset and progress at a slower rate than DMD.
30

Currently, no cure exists for this disease. People suffering BMD are encouraged to remain

active by participating in physical therapy.

1.2.1.3 Limb-Girdle Muscular Dystrophies
The family of Limb-Girdle Muscular Dystrophy (LGMD) is a group of heterogeneous
disorders that affect voluntary muscle movement in the hips and shoulders. (Fig 1.2B) Mutations
occur in several genes coding for crucial proteins localized in nucleus, cytosol, or cell
membrane. Over 30 subtypes of LGMD have been identified, the majority of them are autosomal
recessive myopathies.30 LGMD classification criteria committees assign the number 1 if there is
a subtype with dominant heritage or number 2 if affected people present a recessive form. Due to
diversity in phenotype, following the assigned number indicating dominant or recessive heritage
LGMD, a letter is added (A to W). The letters are added in the order of discovery and indicate
distinct genetic mutation. Prevalence of LGMD is variable depending on characteristics of
ethnicity in particular populations, suggesting a potential genetic founder effect.31 The
progressive nature of this group of muscular dystrophies leads to a considerable loss of muscle
strength, high levels of creatine kinase (CK), calf hypertrophy, and scapular winging.32 Similar
to dystrophinopathies, most LGMD subtypes show membrane impairment and chronic
inflammation.33 However, each subtype of LGMD entails a distinct mutation in genes coding for
dysferlin, telethonin, calapain, the sarcoglycan complex, and the fukutin-related protein (Fig
6

1.3). Diagnosis of LGMD is a complex process. Currently, specific diagnostic tools, including
next generation sequencing and magnetic resonance imaging of the muscle or thoracic cavity,
have proven beneficial in providing data about affected muscles. Additionally, these diagnostic
tools can be a valuable guide for performing the proper muscle biopsy and helping to focus on
specific genetic testing.

Figure 1.3. Dysferlinopathies. Light blue boxes are representations of some proteins involved in different types of
dysferlinopathies. (Adapted from: https://pubmed.ncbi.nlm.nih.gov/25252238/ and created by BioRender.com

1.3

Limb-Girdle Muscular Type 2B (LGMD2B)
Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B or LGMDR2) is an autosomal

dysferlinopathy caused by mutations in the DYSF (dysferlin gene) located on chromosome 2p13.
Transcripts coded by the DYSF encompasses 55 exons and alternative splicing leads to various
7

isoforms.34 Among them, isoform eight is normally used to refer to dysferlin, a 230 kDa
protein.34,35 The dysferlin protein is predominantly localized in the sarcolemma.36 Dysferlin is
also expressed in different tissues including the bone marrow, placenta, heart, and spleen. It is
related to multiple cellular functions including vesicle fusion, protein trafficking, and repair of
damaged membranes.36, 37 Dysfunctional dysferlin protein leads to manifestation of LGMD2B
pathology including alterations in Ca2+ homeostasis during mechanical stress, increases in
inflammation, delayed removal of necrotic muscle fibers, reduced myogenic potential, muscle
atrophy, increased lipid infiltrate, and diminished membrane repair.38 Clinical characteristics of
the disease include: muscle weakness and atrophy of muscles of the pelvic and shoulder region,
loss of ambulation, difficulty running, climbing stairs, and walking, inability to stand without
assistance, and heightened creatine kinase levels.
Despite a relatively high prevalence in certain ethnic populations, LGMD2B is
considered a rare muscular dystrophy, affecting 1 in 100,000 to 200,000 people.39 The age of
onset of muscle weakness is extremely variable, but it occurs most commonly in adolescence and
early adulthood. Dysferlin deficient patients present impaired repair of the plasma membrane in
the limb-girdle affected muscles.34, 40 This impairment in the plasma membrane leads to
debilitation of proximal muscles in dysferlin-deficient patients.41 Additionally, dysferlindeficient models show defective muscle differentiation due to delayed development of the
myogenesis, the process in which satellite cells become mature myotubes.42
Commonly, muscle tissue is exposed to mechanical stress leading to plasma membrane
disruptions. Although dysferlin-deficient models do not seem to be more prone to membrane
disruption than normal muscle, strong evidence indicates that the membrane repair process may
be compromised in dysferlinopathies.41 This feature can be significantly exacerbated in animal
8

models by enforcing eccentric and concentric exercises intended to maximize mechanical forces
on tissues.43 Furthermore, Bansal et al. stated that dysferlin is involved in vesicle recruitment
when resealing the sarcolemma after injury.41 Initial diagnosis of dysferlinopathies include
assessment of strength in regions that involve proximal limb muscles and marked elevation of
CK levels.44 In dysferlin-deficient mice models, muscle degeneration is a consequence of
disruption of the muscle membrane repair machinery.45
The multifaceted roles of dysferlin in muscle have made a cure or clinically meaningful
treatment elusive. While additional studies will be required to fully understand the mechanism of
the dysferlin in LGMD2B, current treatment options available to patients are chiefly palliative in
nature and focus on maintaining ambulation.

1.3.1 Mouse Models
There are several spontaneous and engineered dysferlin-deficient mouse strains available
to study LGMD2B. Dysferlin-deficient mouse models have been classified depending on degrees
of severity. SJL/Jdysf-/- (SJL/J) and A/Jdysf-/- (A/J) mice are two naturally occurring dysferlindeficient models with phenotypical characteristics developing muscular dystrophy.46, 47 SJL/J
contains an inherited splicing mutation on the chromosome 6, in a syntenic region with the
human chromosome 2p13.46 Similarly, the A/J strain has a distinctive ETn retrotransposon
insertion within intron 4 and develops progressive dysferlinopathy .47 Both, SJL/J and A/J
models are prone to develop different levels of muscle regeneration and inflammatory response
in muscles compared to the C57BL/6, the wild type strain most commonly used in biomedical
research .48-52
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One of the most explored models in dysferlinopathies is the B6.A-Dysfprmd/GeneJ
(BLA/J) mice. This is a backcrossed strain between A/J on C57BL/6 background with an
engineered mutation where an ETn retrotransposon (5-6kb) is inserted in intron 4 of the DYSF
gene.49 BLA/J mice have reduced vulnerability to infections compared to the SJL/L and A/J
mice.53
According to the Human Gene Mutation Database (HGMD, 2020), dysferlinopathies in
humans show a broad range (~577) of variants. Most of the reported mutations in this disease
consist of insertions, deletions, and point mutations that are found dispersed in between intron 1
to exon 54 of the DYSF gene.54, 55 This research presents results based on experiments in BLA/J,
A/J and C57BL/6 mouse strains.

1.4

Introduction to Membrane Repair
In general, cells are under mechanical and chemical stresses that promote membrane

disruption.56 The plasma membrane is a phospholipid bilayer structure that separates cells from
the external environment. It is responsible for protecting and maintaining homeostasis to prevent
cell death.57 Plasma membrane disruption is a common type of cellular injury and rapid repair is
requisite to avoid cell death. McNeil et al. state that membrane disruption and repair occur in
vivo.58 During the repair process, intracellular vesicles are recruited to form a repair patch, which
is dependent on intracellular Ca2+. Vesicle fusion, in combination with membrane constriction,
work with proteins like dysferlin (a protein that is also Ca2+ dependent) and the annexin protein
family to repair the membrane.59, 60
There is ample evidence that dysferlin participates in membrane repair and the
mechanism is beginning to be uncovered. Defour et al. showed that dysferlin protein regulates
10

membrane repair by releasing acid sphingomyelinase.61 Kerr et al. state that dysferlin is enriched
in the t-tubules and that the main function of dysferlin may be directly associated with this
structure rather than the sarcolemma membrane.62, 63 Moreover, dysferlin helps in stabilizing the
membrane when interacting with the SNARE protein, phosphatidylserine (PS), and other lipids
in the cell membrane.64
Currently, there are a variety of ongoing studies to find therapies to help in repair of the
membrane in different types of muscular dystrophies. Mitsugumin-53 (MG53), also known as
TRIM72, is a 53-kDa protein involved in plasma membrane repair of skeletal muscles and other
tissues.64 Gushchina et al. explain that exogenous MG53 interacts with membrane disruptions
sites and increases repair in mdx mice, a mouse model for DMD.65 Additionally, MG53 showed
therapeutic potential by improving skeletal fiber integrity in LGMD2B mice models.65 Gal-1 has
also shown therapeutic potential in mdx mice.
Administration of steroids is another developing therapy that aims to reduce sarcolemma
lipid mobility and aid membrane stability. Vamorolone, a well-known glucocorticoid, has been
shown to facilitate repair by successfully stabilizing damaged muscle membranes of dysferlindeficient myoblasts.66-68 These molecules may prove to be important muscle therapeutics due to
their ability to provide structural support, maintain homeostasis, and prevent pathological
symptoms and cell death.

1.5

Introduction to Inflammation
Inflammation is an essential defense mechanism involving cellular and humoral response

to harmful stimuli caused by foreign invaders, endogenous signals, and mechanical or chemical
damage.69 Acute or short-term inflammation, characterized by pain, redness, loss of function,
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swelling, and heat, occurs as a response to tissue injury.70 71 Alleviation of acute inflammation
helps to restore tissue homeostasis. Conversely, uncontrolled acute inflammation leads to a range
of chronic inflammatory diseases.72, 73 Sustained chronic and destructive inflammation
accompanying muscle degeneration and immune response are characteristics of muscular
dystrophies.74-76 Because loss of muscle mass, degeneration, and necrosis are associated with
proliferation of proinflammatory cytokines in multiple types of muscular dystrophies, it is crucial
to understand how inflammatory modulation may provide approaches to treat muscular
dystrophy.77
Endogenous mediators, including anti-inflammatory agents, are critical in controlling the
inflammatory response.78 Gal-1, a lectin protein that binds to specific glycan structures, has
shown involvement as an anti-inflammatory regulator in a variety of physiologic and pathologic
processes.78-81 Furthermore, Gal-1 decreases chronic inflammation in dysferlinopathies by
increasing myogenesis and improving membrane repair capacity.42

1.6

Introduction to Galectins
Galectins are a superfamily of soluble β-galactoside-binding proteins that occur in the

cytoplasm, plasma membrane, and extracellular matrix. Galectins were discovered in hepatic
cells during the 1970’s and originally referred as S-type lectins because of their sulfhydryl
groups in cysteine residues.82 These proteins are characterized by containing one or two highly
conserved carbohydrate recognition domains (CRD). It is important to note that just a few
residues of the CRD in galectins make direct contact with the glycan ligands.82
There are 15 types of galectins found in mammals classified in three main groups according
to their CRD arrangement.83 Prototypes galectins (galectin-1,-2,-5,-7,-10,-11,-13,-14, and -15)
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contain one or two identical CRDs.84 Tandem repeat galectins (galectin-4, -6,-8, -9 and -12)
contain two different CRDs. Chimeric galectin (galectin-3) contains a distinctive N-terminal
region allowing oligomerization with another galectin-3.85 Galectin’s classification is described
in the Fig.1-4. Galectins are involved in several physiological roles. Researchers have
established that outside the cell, galectins bind to cell membrane.83 Galectins are also found in
the cytosol and nucleus. They are involved in cell functions such as cell migration, cell signaling,
immune response, protein-protein interaction, and inflammation.84 Gal-1, was the first animal
cell lectin to be described. This protein is expressed in both normal and pathological tissues with
a wide range of extra and intra cellular biological activity.

1.6.1 Galectin-1
Gal-1 is a non-glycosylated protein encoded the LGALS1 gene with a phylogenetically
conserved CRD.86 Gal-1 can be found as a monomer (mGal-1) or dimer (dGal-1) in a reversible
monomer-dimer equilibrium, each known to have unique functions. Gal-1 interactions have been
shown to induce diverse physiological activities such as extended glycan stabilization, cell
migration, cell growth and adhesion, absorption of reactive oxygen species, and angiogenesis.81,
87

Additionally, Gal-1 has a strong anti-inflammatory response in acute inflammation.88
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Figure 1.4. Classification of Galectins. Diagram showing different types of Galectins. Adapted from https://tinyurl.com/ywya8e2p.
Created by BioRender.com.

Structurally, Gal-1 has a β-sandwich domain with two antiparallel sheets of five and six
strands (Fig. 1.5). Gal-1 contains six cysteine residues, which make it particularly sensitive to
oxidation. 81, 89 Oxidized Gal-1 contains three intramolecular disulfide bridges (Cys2-Cys130,
Cys16-Cys88, and Cys42-Cys60) which inactivate the CRD through conformational changes.
However, oxidized Gal-1has its own unique interactions that stimulate axonal regeneration in
rats.81, 90 Gal-1 forms dimers in a concentration dependent manner. Studies have demonstrated
that dimeric Gal-1 is critical in extracellular lattice formation.91 Gal-1 binds to Nacetyllactosamine (LacNAc) units at the branches of N- or O-linked glycans on a diversity of cell
surface receptors and modulates their segregation, endocytosis, and signaling (Fig.1.6).92, 93
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mGal-1 and dGal-1 in oxidized and reduced form must be evaluated in order to better understand
the diverse functions of this protein.
Gal-1 regulates several biological processes extracellularly, by cross-linking cell surface
glycoconjugates, or intracellularly, by influencing a variety of signaling events.91 Gal-1 shows
upregulated levels in injured muscles and in models of muscular dystrophy such as in mdx mice
compared to wild type (WT) mice (C57BL6).94 Van Ry et al. showed that treatment with
exogenous recombinant Gal-1 improves muscle function in mdx mice.95 We also found that in
vitro and in vivo Gal-1 treatment upregulates the expression of Gal-1, indicating a positive
feedback loop.42 Because of its remediating effects in DMD, its prominent anti-inflammatory
properties, and its role improving myogenesis and membrane repair, 42 Gal-1 is a promising
therapeutic alternative for treating muscle diseases.

Figure 1.5. Crystal Structure of Galectin-1. Galectin-1 showing 6 Cys residues (pink)and bound to generic βgalactoside ligand (Modeled from PDB 4Y1U). Created by PyMol.
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Figure 1.6. Crystal Structure of Galectin-1. Galectin-1 showing bound to generic β-galactoside ligand (Modeled
from PDB 4Y1U). Created by PyMol.

1.7

Treatment and Therapies
Muscular dystrophies have several mutations and vary in progression and severity (Table 1).

Because of that, it is a challenge to develop approaches leading to treat or cure this group of
diseases. The only treatments available for LGMD2B are palliative in nature. However, recent
work has explored potential therapies. We will explore a few prominent therapies in the follow
sections.
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1.7.1 Steroids Therapy
Since the early 1970’s, lower doses of corticosteroids have been used as initial therapies
to treat DMD.96 Scientists have shown that time-specific corticosteroid treatment can stabilize
muscle strength, improve membrane repair, and modulate gene expression in murine models.97, 98
The particular mechanism of steroid regulation for DMD treatment is still unknown.
Administration of prednisone, a corticosteroid, improves muscle function and ambulation of
DMD patients by slowing muscle degeneration.97, 99 Although the mechanism is not fully
understood, prednisone helps to improve muscle function by decreasing expression of nuclear
proinflammatory markers.100 Side effects of prednisone include changes in behavior,
immunodeficiency, cardiac issues, and metabolic disturbances.101, 102 While glucocorticoids are
commonly used in DMD, frequency in administration plays a key role in positive outcomes of
non-Duchenne muscular dystrophies. Weekly administration of prednisone (in comparison to
daily administration) reduced muscle damage and decreased adipogenesis in dysferlin-deficient
models.103
Deflazacort is a prednisolone-derived glucocorticoid with anti-inflammatory and
immunosuppressant properties.104 Similar to prednisone, deflazacort improves muscle strength in
DMD patients. However, this glucocorticoid led to less weight gain than prednisone.105 Although
prednisone and deflazacort show increasing muscle functionality in DMD patients, both of them
are not effective therapies for dysferlinopathies.66, 106
Vamorolone (VBP15), a dissociative steroid that works in similar way to other
corticosteroids, has shown evidence of being safe and effective in DMD.107 This dissociative
steroid, can also be used to treat dysferlinopathies.108 It has been associated with transrepression,
tissue remodeling, and other physicochemical effects on the membranes. Sreetama et. al showed
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that Vamorolone improves muscle functionality, membrane stability, and repair in LGMD2B
mice models.66, 109 Additionally, Vamorolone decreases sarcolemma lipid mobility which has
beneficial effects in dysferlin-deficient mouse models.66 Steroid treatments help to mitigate
symptoms in the absence of a cure for muscular dystrophies. However, these treatments only
delay inevitable disease progression in muscular dystrophy patients and have sub-activities that
lead to side effects that detract from patient quality of life.

1.7.2 Gene and Cell Therapies
Gene and cell therapies have received increased attention in recent years. Therapeutic
cells can be isolated from a diseased or a healthy donor patient and either rectified in ex vivo or
introduced into a muscular dystrophy patient, respectively.110 Gene therapy is the process of
directly inserting a vector into the patients to correct or remove the mutated genes.110, 111 Both
gene and cell therapies are complementary and have multiple approaches.
In DMD, scientists fuse corrected or healthy therapeutic cells to develop a successful
method to enhance muscle repair.112 In addition to muscle repair, muscle stem cells express
PAX7, an early transcription factor responsible for initiating myogenesis and helping
transplanted myoblasts become muscle precursor cells.42, 112, 113 Studies on bone marrow
transplants for DMD patients are currently in preliminary stages.114 Additionally, studies
involving cell therapy report encouraging outcomes in patients affected by other dystrophies
including oculopharyngeal muscular dystrophy (OPMD). While cell-based therapies are
currently considered promising methodologies to treat muscle diseases, specific methods and
strategies for cell delivery are required to observe acceptable results in other types of muscular
dystrophies.115-117
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Contractile capacity in muscles is a crucial target in gene therapy.114 Since deletions have
been the most recurrent mutations observed in DMD and BMD patients, scientists are
researching methods to correct exon skipping to keep the functionality of dystrophin protein.114,
118

Exon 51, 53, and 45 are the most mutated and drug targeted exons in DMD.119 Currently,

viltolarsen, eteplirsen, and golordisen have been given conditional approval as gene therapy
strategies to restore dystrophin gene activity. Other studies in DMD show that some
adenoviruses have been used safely as therapeutic vectors to measure the gene therapy responses
in porcine, canine, and murine models of this disease.114 Because dystrophin is so large, it limits
the packaging capacity in the adenovirus. To overcome this obstacle, a short version of the gene
(mini dystrophin) has been used as a therapy to improve quality of life in muscular dystrophy
patients.111, 114, 118

1.7.3 Protein Therapy
Proteins are macromolecules that display a wide range of functions in the body.120 Protein
therapies employ recombinant proteins to solve health issues in the body. This approach provides
successful results that ameliorate a wide range of pathologies.121 Since the initial recombinant
human insulin was introduced as a beneficial treatment to regulate blood sugar levels, protein
therapies have become involved in several spheres of medicine. However, for muscular
dystrophies, this significant avenue is still in its early development.122 Currently, there are more
than 100 protein therapeutics linked to either clinical uses or other pharmacological activities
that use protein as successful novel therapies participating in numerous clinical assays.120, 121
Therapies based on proteins can also be grouped by their pharmacological activity, types of
molecules, mechanism of action, nature, and availability of recombinant proteins.123, 124 High
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specificity, physiological production, and reduced time of approval are three significant
advantages of the proteins treatments compared to other therapies.121, 123, 124 Here, we portray the
therapeutic characteristics of two key proteins with specific functions in different types of
muscular dystrophies.
Mitsugumin 53 (MG53) is a member of tripartite interaction motif (TRIM) family of
proteins.125 This 53 kDa protein that comprises a ring finger and a coiled-coil region at the C-and
N-terminus, is an important constituent of the sarcolemma repair machinery.126 Therapeutic roles
of MG53 are linked to a variety of factors, including Ca2+ homeostasis, myogenesis, and
membrane repair capacity in skeletal muscle diseases.65, 125-127
MG53 regulates Ca2+ through the SPRY domain when complexing with Orai1, a Ca2+
release-activated Ca2+ channel protein.128 The MG53-Orai1 complex stimulates skeletal muscle
contractions by modulating the release and storage of extracellular and intracellular Ca2+.126
Scientists have demonstrated that Ca2+ homeostasis plays a key role in membrane repair.125, 126,
129-131

Upon injury, extracellular Ca2+ intake activates a cascade of intracellular proteins,

including MG53, dysferlin annexin A1, annexin A5, and caveolin-3, that rapidly fuse to slow the
damage of the cell membrane.127, 129, 130 MG53 works as a therapeutic to improve the viability of
this protein cascade. This therapeutic approach has been validated for a variety of animal
models.59, 125, 132-134
In a recent article, Zhang et al. reported that MG53 protein negatively modulates myogenesis
in C2C12 myoblasts.125 The constraint of myogenesis is a result of ubiquitination of the insulin
receptor 1 (IRS-1), an essential ligand in the insulin response that drives inhibition of the insulinlike growth factor 1 (IGF-1), a growth factor that affects almost every cell in the body.135, 136 On
one hand, MG53 exhibits a variety of therapeutic roles related with Ca2+ homeostasis and repair
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of the membranes. However, adverse effects on myogenesis are still limiting the potential impact
of this protein as a treatment for muscle diseases.
The annexin (ANX) protein family is biochemically characterized as a group of soluble
proteins that reversibly bind to phospholipids in a Ca2+ dependent manner.137 The structure of
each ANX display interesting features which include two major domains, a Ca2+ conserved core
at the C-terminus and a high specificity variable domain at the N-terminus.138 ANXs are usually
localized in a stable form in the cytosol, and in some circumstances ANXs have been found in
nucleus and cell surface. 133, 137-139 Levels of expression of ANXA1 in the cell membrane are
linked to the exposure of cell to glucocorticoids.140ANXA5 is linked to the exposure of
phosphatidylserine (PS) to the cell surface in a galectin-1 dependent manner and is involved in
the mechanism of repairing in human muscles skeletal cells.141, 142 ANXA6 is located in the
plasma membrane and is implicated in vesicle function, cholesterol transport, and membrane
repair.133, 143, 144 Each of the abovementioned ANXs (A1, A2, and A6) have been linked to
membrane repair in muscle cells and are considered targets for therapeutic development in
muscle diseases.
In 2019, Demonbreun et al. showed that treatment with recombinant ANXA6 helps repair
the membrane and reduce damage during muscle disruption. In this study, researchers stated that
the [Ca2+]-ANXs (A1, A2, A6) interactions take part in a crucial role during muscle injury and
repair cap formation. 133 During the injury-repair process, Ca2+ fluorescence and ANXs (A1,A2,
A6) expression were linked to sizes of observed blebs at the injury site in myofibers.133
However, expression of ANXA6 was inversely proportional to the Ca2+ fluorescence and bleb
sizes.133 Although additional studies are required to determine the accurate therapeutic impact of
this treatment, these results indicate that in a Ca2+ dependent manner, the treatment with
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recombinant ANXA6 benefits the cell by protecting the membrane of dystrophic and nondiseased injured fibers.

1.8

Summary
The central hypothesis of this dissertation is that Gal-1 is a beneficial protein therapy for

treatment of LGMD2B. This dissertation provides evidence in in vitro and in vivo models of
LGMD2B that recombinant human galectin-1 (rHsGal-1) protein positively affects muscle cells
by modulating muscle formation, membrane repair, and inflammatory response.
Chapter 2 examines the impact of Gal-1 treatment as a promising protein therapy using in
vitro and ex vivo dysferlin-deficient models. To explore the implications of Gal-1 treatment in
muscle formation and membrane repair, we used dysferlin-deficient A/J (A/J-/- and A/J+/+) cells
and (Dysf-/- and BLA/J) myofibers. First, to determine the impact of this protein treatment on
myogenesis and membrane repair, A/J-/- confluent myoblasts were differentiated and non-treated
or treated with rHsGal-1 for 48-72h. Results from this study show that rHsGal-1 treated A/J
myotubes had improvements in size, myotube alignment, myoblast migration, and membrane
repair capacity.42 Second, to confirm if tissue level data would match cell level data, explant
myofibers from two different types of dysferlin-deficient mice (BlA/J and Dysf-/-) were used.
These explant experiments showed that Gal-1 improves membrane repair capability in these
dysferlin-deficient models.42 Additionally, the results show that the CRD is an important
structure that Gal-1 use in membrane repair. Another key feature in this research is that rHsGal-1
exhibited normal membrane repair functionality independent of Ca2+ as shown in A/J-/- and A/J+/+
(WT) myotubes and BlA/J myofibers.42
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Chapter 3 describes the methods used to evaluate the therapeutic activity of Gal-1 in muscle
sarcolemma repair. Here, biochemical characteristics of Gal-1 and its role to modulate muscle
disease pathologies are described. UV Laser ablation, a key technique to measure membrane
repair capability, and modified FRAP assays were used to produce precise injuries. Additionally,
methods for measuring protein-colocalization, CRD lactose dependent functionality, calcium
regulation, and how to use labeled and unlabeled Gal-1 in live confocal laser injury and imaging
were explained in this chapter. Our results show that Gal-1 stabilizes the membrane through
interactions with the CRD and independent of Ca2+.
Chapter 4 focuses on examining the role of Gal-1 in membrane repair and the modulation of
the NF-κB inflammatory pathway in a short-term in vivo study using murine models of
LGMD2B and patient-derived dysferlin-deficient human myotubes. Additionally, this chapter
shows rHsGal-1 may decrease muscle fat deposition in BLA/J mice. Structurally, rHsGal-1 is
similar to WT Gal-1 except for the inclusion of a 6x His-tag on the C-terminus in rHsGal-1,
which aids in purification and epitope binding for assays. Our results indicate that BLA/J mice
treated with rHsGal-1 showed increased membrane repair capabilities in comparison to PBS
treated mice and dysferlin-deficient human myoblasts. Treatment with rHsGal-1 decreases levels
of inflammatory markers p65, p50, and TAK1 in the NF-κB pathway in LGMD2B models.
Additionally, overexpression of IL-4, an anti-inflammatory cytokine, was observed in the
secretome of the co-cultured A/J-/- myotubes and BLA/J muscles macrophages treated with
0.11µM rHsGal-1 for 48h when compared with non-treated. These results indicate that in
addition to LGMD2B, Gal-1 treatment can attenuate some of the inflammatory response
associated with muscle or non-muscles diseases.
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In chapter 5, preliminary data related to endocytosis, exocytosis, and macrophage
polarization is put forth, and conclusions and futures directions are considered. Our preliminary
data show that endo- and exocytosis are two crucial processes involved in membrane repair.
Additionally, in a one-week treatment with rHsGal-1, BLA/J mice exhibited a decrease in
inflammatory macrophages (M1) and an increase in anti-inflammatory macrophages (M2). After
a one-month treatment with rHsGal-1, M1 macrophages remained reduced, although the M2
population returned to saline-treated levels.
Although the long-term impact of this rHsGal-1 needs to be investigated, the data produced
in pursuing my PhD provide strong evidence and suggest the importance of continued research to
develop this protein therapy as a potential therapeutic option for people suffering from muscular
dystrophies, including LGMD2B.
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CHAPTER 2: GALECTIN-1 TREATMENT IMPROVES MYOGENIC
POTENTIAL AND MEMBRANE REPAIR IN DYSFERLIN-DEFICIENT
MODELS

Vallecillo-Zúniga, M.L., Rathgeber, M.F. et al. Treatment with galectin-1 improves myogenic
potential and membrane repair in dysferlin-deficient models. PLOS ONE 15, e0238441 (2020).
DOI: 10.1371/journal.pone.0238441

Abstract
Limb-girdle muscular dystrophy type 2B (LGMD2B) is caused by mutations in the
dysferlin gene, resulting in non-functional dysferlin, a key protein found in muscle membrane.
Treatment options available for patients are chiefly palliative in nature and focus on maintaining
ambulation. Our hypothesis is that galectin-1 (Gal-1), a soluble carbohydrate binding protein,
increases membrane repair capacity and myogenic potential of dysferlin-deficient muscle cells
and muscle fibers. To test this hypothesis, we used recombinant human galectin-1 (rHsGal-1) to
treat dysferlin-deficient models. We show that rHsGal-1 treatments of 48 h-72 h promotes
myogenic maturation as indicated through improvements in size, myotube alignment, myoblast
migration, and membrane repair capacity in dysferlin-deficient myotubes and myofibers.
Furthermore, increased membrane repair capacity of dysferlin-deficient myotubes, independent
of increased myogenic maturation is apparent and co-localizes on the membrane of myotubes
after a brief 10min treatment with labeled rHsGal-1. We show the carbohydrate recognition
domain (CRD) of Gal-1 is necessary for observed membrane repair. Improvements in membrane
repair after only a 10 min rHsGal-1treatment suggest mechanical stabilization of the membrane
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due to interaction with glycosylated membrane bound, ECM or yet to be identified ligands
through the CRD domain of Gal-1. rHsGal-1 shows calcium-independent membrane repair in
dysferlin-deficient and wild-type myotubes and myofibers. Together our novel results reveal
Gal-1 mediates disease pathologies through both changes in integral myogenic protein
expression and mechanical membrane stabilization.

2.1 Introduction
Limb-girdle muscular dystrophy 2B (LGMD2B) belongs to a family of muscular
dystrophies called dysferlinopathies. The incidence of this disease ranges from 1:1,300 to
1:200,000, with certain geographic locations and ethnic populations more heavily impacted than
others.39, 145, 146 Patients with this disease present muscle degeneration and weakness beginning in
the second decade of life and often exhibit complete loss of ambulation by the third decade of
life.
Symptoms of LGMD2B stem from mutations in the DYSF gene, which encodes for the
dysferlin protein. Dysferlin is a 230kDa transmembrane protein heavily involved in Ca2+
signaling in adult myocytes.147 Mutations to the dysferlin protein lead to aberrant Ca2+ signaling,
causing poor membrane repair, myogenesis, and muscle degeneration.147-152 Dysferlin-deficient
myoblasts show decreased myogenesis, but the direct influence of dysferlin on this process is
unclear.153 Membrane repair is a complex process involving multiple pathways with the purpose
of restoring compromised membrane integrity.
Current drug treatments for LGMD2B are limited and focus on mitigating the effects of
chronic inflammation. Other palliative treatment options include muscle strengthening and
patient education regarding preventative measures to reduce muscle injury. There is an unmet
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need in the field for viable long-term therapeutic options. Glucocorticoid treatments have been
used to modulate impaired membrane stability and inflammatory response in many muscular
dystrophies.103, 109 However, regular glucocorticoid treatment has marginal or detrimental effects
in patients with LGMD2B.109, 154 Therefore, due to the lack of current viable treatments, a
therapeutic that can increase myogenic potential and membrane repair would be most beneficial
to patients and their families.
Galectin-1 (Gal-1) is a small, non-glycosylated protein encoded by the LGALS1 gene with a
CRD which is highly conserved between all mammals with an 88% homology. 81, 95, 155-157
Mouse and human Gal-1 have minor structural differences, but the carbohydrate recognition
residues are 100% conserved.158 Mice lacking Gal-1 showed a reduction in myoblast fusion and
muscle regeneration.159 Recombinant human galectin-1 (rHsGal-1) has shown efficacy in
reducing disease pathologies in murine models of Duchenne Muscular Dystrophy (DMD)
through positive regulation of myogenesis and stabilization of the sarcolemma.95 Since previous
research using rHsGal-1 was similar to those reported using recombinant mouse Gal-1 in a DMD
mouse model, we chose to use rHsGal-1 in our study. Although Duchenne Muscular Dystrophy
and LGMD2B have different etiologies, they share similar pathologies such as diminished
membrane repair, poor muscle regeneration, and chronic inflammation. Therefore, Gal-1 poses
as an effective treatment option in increasing myogenesis and membrane repair in LGMD2B.We
hypothesize that the addition of exogenous recombinant human galectin-1 (rHsGal-1) will
improve myogenic regulatory factors and increase membrane repair capacity, resulting in more
robust muscle formation in models of LGMD2B.
We explore the effects of rHsGal-1 treatment in A/J dysferlin-deficient (A/J-/-) cells and
ex-vivo muscle assessment using Dysf-/- (B6.129.Dysftm1Kcam/J), BLA/J (B6.A27

Dysfprmd/GeneJ), and BL/6 (C57BL/6) mice. This study shows that Gal-1 treatment increases
myogenic transcription factors leading to enhanced myotube formation in A/J-/- myotubes and
increased membrane repair capacity in A/J-/- myotubes as well as Dysf-/- and WT myofibers.
Additionally, this work reveals that the CRD of Gal-1 is necessary for improved repair capacity
and that the impact of Gal-1 on membrane repair is Ca2+-independent in both diseased and nondiseased models. Together, these findings will broaden Gal-1 therapeutic applications to include
LGMD2B models.

2.2:

Materials and Methods

2.2.1 Recombinant human Galectin-1(rHsGal-1) production and purification
The human Galectin-1 gblock LGALS1 gene fragments were produced as doubled-stranded
DNA using high fidelity polymerase (Integrated DNA Technologies, Coralville, IA). The
LGALS1 gblock was cloned into the pET29b (+) vector (kindly provided by Dr. James Moody)
using NEBuilder® HiFi DNA Assembly Cloning Kit (E552OS New England Biolabs (NEB),
Ipswich, MA). The product was purified following the E.Z.N.A.® Plasmid DNA Mini Kit I
protocol (Omega Bio-Tek, Inc. Norcross, GA) and the DNA sequence was confirmed by EtonBioscience, Inc. (San Diego, CA). The cloned vector was transformed into BL21(DE3)
competent E. coli cells (High Efficiency, NEB # C2527H) grown and induced with 0.1mM IPTG
(Invitrogen). rHsGal-1 was purified using the Cobalt Talon Metal Affinity Resin protocol
(Takara Bio USA, Inc, Mountain View, CA) in a poly-prep® Chromatography column (Cat #
731-15550, Bio-Rad, Richmond, CA) and imidazole elution buffer. Purified rHsGal-1 was then
filtered and dialyzed three times for a total of 24h in PBS at 4oC. Endotoxin levels were
measured using LAL Chromogenic Endotoxin Quantitation Kit (Cat # 88282, Thermo Scientific
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Rockford, IL). All endotoxin levels of purified rHsGal-l were below the FDA limit of 0.5EU/ml
at >0.1EU/ml. Purified rHsGal-1 was conjugated with Alexa Fluor 647 following the protocol
provided with the protein labeling kit (Molecular Probes, Cat No. A20173, Eugene, OR) with a
few alterations as described in Stowell et.al.160 The concentration of both rHsGAL-1 and Alexa
Fluor 647 labeled rHsGal-1was determined with the Pierce™ BCA Protein Assay Kit
(ThermoScientific, Cat. No. 23225, Rockford, IL).
Monomeric Galectin-1 was constructed, produced, and generously provided by Stowell Lab
at Emory University. All other Galectins (dGal-1, BioID2-Gal-1, and miniturboID-Gal-1)
nucleotide sequences were constructed in SnapGene (GSL Biotech, Chicago, IL). Vector
assembly was completed by Twist Bioscience (San Francisco, Ca). Transformation and protein
induction were performed as previously stated. Galectin purification was accomplished passing
bacterial lysate through Lactosepharose column (Sigma-Aldrich, St. Louis, MO). Galectin was
eluted with 14mM βME and 100mM Lactose in 1X PBS. Protein fraction absorbance was read
on BioPhotometer (Eppendorf, Hamburg, Germany) and fraction with a 280nm absorbance of ≤
.5 were kept and stored in 80˚C. To activate the CRD, factions were passed over a PD-10
desalting column (GE Health Care, Chicago, IL) and stored at 4˚C.

2.2.2

Cell culture
Immortalized murine myoblasts H2K A/J-/-, [A/J-/-], (Clone #13-1,10/28/09) and H2K A/J

WT, [WT], (Clone #16, 6/9.2010), kindly provided by Dr. Terence A. Partridge (Center for
Genetic Medicine research, Children’s National Health System, WA, DC) were cultured as
described in Morgan.et al161 and Jat et al.162 Myoblasts were then plated onto glass-bottomed,
collagen coated dishes sterilized with gamma-irradiation (MatTek, Part No: P35GCOL-1.0-14-C,
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Ashland, MA), seeded at a density of 5,555 cells/cm2 and incubated at 33°C in 10% CO2.
Myotubes were obtained from confluent myoblasts after 2 to 4 days in differentiation media
supplemented with or without rHsGal-1 (0.014µM-0.22µM). Differentiation media and
treatments were changed every other day. RAW 264.7 TIB-71™ Macrophages (ATCC,
Manassas, VA) were plated on non-treated 100 mm culture dishes (Corning®, Corning, NY) at a
cell density of 10,900 cells/cm2. Macrophages grew until 80-90% confluency (3-4 days) and
were harvested using ice cold 5mM EDTA in 1X PBS. Macrophages incubated for 40 min and
then were gently wash and centrifuged at 900 x g for 8 minutes.

2.2.3

Western blotting
Myotubes (at 2 to 4 days) were obtained as described above. Whole cell lysates were

prepared using RIPA lysis buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS, 140mM NaCl, and 1mM PMSF) and Halt™ Protease
and Phosphatase Inhibitor Single-Use Cocktail (100X) (Cat No. 78442, ThermoScientific).
Protein concentration was determined using the Pierce™ BCA Protein Assay Kit
(ThermoScientific). Proteins samples were separated under standard conditions on 6%-20%
SDS-PAGE gels and transferred onto Nitrocellulose Membranes 0.2µm (Bio-Rad, Cat
No.1620150, Hercules, CA) through electro blotting. After blocking with 5% w/v non-fat dry
milk in 1X TBST), membranes were probed overnight for the following mouse, rabbit, or goat
monoclonal and polyclonal antibodies: 6x-His Tag Monoclonal Antibody (HIS.H8), (Cat. No.
14-6657-80 Invitrogen,1:1000), Galectin-1 Monoclonal Antibody (6C8.4-1) (Cat. No. 43-7400,
Invitrogen 1:1000), Myogenin (FD5, DSHB, 0.2µg/ mL, Pax7 (DSHB, 0.2µg/ mL), Myf5(Cat.
No. PA5-47565, Invitrogen, 1.5µg/mL), MyoD (5.8A, ThermoScientific, 2.5µg/ mL), MHC
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(MF20, myosin, sarcomere, Cat. No. AB_2147781, DSHB, 0.2µg/ mL), Annexin A6 (Cat No.
720161, ThermoFisher Scientific, 2μl), Annexin A1 (Cat. No. 713400, Invitrogen, 1:1000), βTubulin Loading Control, BT7R, (Cat. No. MA5-16308, ThermoScientific, 1: 2,000), GAPDH
(Cat. No. MA5-15738, Invitrogen, Rockford, IL, 1:1000), and Anti-β-actin (Cat. No. A5441,
Sigma-Aldrich, St. Louis, MO. 1: 5,000). After washing primary antibodies, blots were probed
using the following secondary antibodies IRDye® 800CW Donkey Anti-Rabbit IgG (H + L)
(Cat No. 926-3221, Licor, Lincoln, NE, 1: 15,000), Goat anti-Mouse IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor Plus 800 (Cat No. A-32730, Invitrogen, 1: 40,000),
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 680 (Cat.
No. A-21058, Invitrogen, 1: 5,000), and IRDye® 680RD Donkey Anti-Goat IgG (Cat. No. 92668074, Licor, 1:5000) The blots were developed using the Odyssey CLx (Model No. 9140, LiCor, Lincoln, NE). Quantifications were done by using ImageJ as described in Schindelin et
al.163

2.2.4

Immunofluorescence
A/J-/- and A/J WT myotubes cultured onto 35mm Glass Bottom Microwell Dishes (Cat.

No. P35GCol-1.0-14-C, MatTek, Ashland, MA) were fixed in 4% paraformaldehyde,
permeabilized in 0.1% triton X-100 (in PBS) and blocked using MOM IgG blocking solution for
1 h at room temperature. The myotubes were then incubated overnight at 4°C with the
appropriate primary antibody: Alexa Fluor 647/Phalloidin (Cat No. A2287, Invitrogen, 1:50),
Myf5(Cat No. PA5-47565, Invitrogen, 5µg/ml), MHC (MF20, myosin, sarcomere, Cat. No.
AB_2147781, DSHB 2µg/ml, DSHB), CellBrite™ Cytoplasmic Membrane Dyes (Cat No.
30021, Biotium, Fremont, CA, 5µ/ml). Nuclei were counterstained with Hoeschst 33342 (Cat
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No. 62249, ThermoScientific, 1μg/ml) and 4’,6-diamindino-2-phenylindole (DAPI) (Cat No.
62248, Thermo Scientific, 1:500). Blots were probed using the following secondary antibodies:
Fluorescein (FITC) AffiniPure Rabbit Anti-Goat IgG, Fc fragment specific (Cat. No. 305-095046, Jackson Immune Research laboratory, West Grove, PA, 1:50), Goat anti-Mouse IgG (H+L)
Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Cat. No. A32723,
ThermoFisher, 10μg/ml), Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary
Antibody, Alexa Fluor 680 (Cat. No. A21058, ThermoFisher, 10μg/ml). Myotubes were
mounted on coverslips using ProLong™ Diamond Antifade Mountant (Cat No. P36965,
Invitrogen) and dried overnight. Images were taken on the A TCS SP2 two-photon confocal
scanning microscope with LASX imaging software (Leica Microsystems Inc., Buffalo Grove,
IL). 647rHsGal-1 inside-outside fluorescent values were obtained as described in Fitzpatrick et
al. 164 Inside-outside ratio was calculated by averaging three ROI from inside a cell and three
ROI between cells per image.

2.2.5

Fusion Index Scoring
A/J-/- and A/J WT myoblasts were plated onto in 35mm Glass Bottom Microwell Dishes

(Cat. No. P35GCol-1.0-14-C, MatTek, Ashland, MA). At 80%-90% confluence, myoblasts were
differentiated as described above and were given treatment (0.11μM rHsGal-1) or not. After
three days in differentiation media and treatment, myotubes were fixed, permeabilized, stained
and imaged as described above. Fusion index was calculated as the number of nuclei contained
within myotubes (cells were considered myotubes if they contained three or more nuclei) divided
by total number of nuclei. Minimum Feret’s Diameter (MFD) was calculated by using ImageJ.
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Myotubes were outlined using the polygon tool, after which the MFD was calculated with the
Feret’s Diameter plugin. Alignment was calculated as described.165

2.2.6

Migration Assay
12-well plates (Cat. No. 83.3921.300, SARSTEDT, Newton, NC) were prepared by

placing a silicone insert (Cat. No. 80209, ibidi culture insert 2 well, Martinsried, Germany) in the
center of each well. A suspension of 145,000 cells/ml (either WT and A/J -/- myoblasts) was
prepared in growth media as described above and 70 µl of the suspension was placed into each
side of the insert. After 2 days, cells were placed in normal differentiation media or
differentiation media supplemented with 0.11µM rHsGal-1 and incubated for 2 days. To form
the wound, the silicone insert was removed 1h prior to first image after washing with PBS; Rate
of migration was calculated over a 48h period. Differentiation media or differentiation media
supplemented with 0.11µM rHsGal-1 was then replaced as described above and directly placed
into the Incucyte®. Magnification was set to 10x and images were taken every 3h for 48h.
Images were analyzed with ImageJ.163

2.2.7

Laser Injury Assay
A/J WT and A/J-/- 0.11µM rHsGal-1 treated or NT myotubes were prepared for laser

injury as described above in 35mm Glass Bottom Microwell Dishes (Cat. No. P35GCol-1.0-14C, MatTek, Ashland, MA). After washing with PBS, the myotubes were incubated for 10min in
PBS enriched with or without: 1mM Ca2+ (as CaCl2), 1µM intracellular (1,2-Bis(2aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid tetrakis (acetoxymethyl ester); (BAPTAAM) (Cat. No. 196419-25MG, EMD Millipore), DMSO as a vehicle (Cat. No. 67-68-5, EMD
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Millipore), 1µM (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; (EGTA)
(Cat. No. 409910250, Acros Organics), 20mM lactose (Cat. No. A11074, Alfa Aesar) or 20mM
sucrose (Cat. No. 57-50-1, Carolina Biological), and 2.5 µM FM™ 1-43 dye (N-(3Triethylammoniumpropyl)-4-(4-(Dibutylamino) Styryl) Pyridinium Dibromide)3,5
(ThermoScientific, Cat. No. T35356, Waltham, MA) for 5min before injury. A TCS SP2 twophoton confocal scanning microscope (Leica) was used to injure the membrane of a myotube or
myofiber and images were taken before and after the injury event. Pre-injury images depict
uninjured myofibers. Myoblasts were not used in injury protocols, only cells with greater than 3
nuclei were counted as myotubes. The myotube was injured with a 405nm UV laser at 100%
power on a HCX PL APO CS 63.0 x 1.40 oil-objective lens. Post-injury images were taken every
5sec for a total of 150sec. Specific settings used as described in Carmeille et al.166 At least three
different myotubes were selected to be injured in each dish. The total change in fluorescence
intensity of FM™ 1-43 dye at the site of the wound for each time point relative to the pre-injury
fluorescent intensity was measured using ImageJ.163

2.2.8

Muscle Fiber Isolation
A 12-well plate (Cat. No. 665 180, Grenier Bio-One) was prepared as described in

Demonreun et al.167 After preparation of digestion plate, C57B6 and Dysf-/- (B6.129Dysftm1Kcam/J) mice were euthanized in accordance with Brigham Young University-approved
protocol. When the mice were sacrificed, hind limbs were removed and the tibialis anterior,
flexor digitorum brevis, and/or gastrocnemius were excised. Next, by using a small-bore pipette,
the fibers were transferred to in 35mm Glass Bottom Microwell Dishes and allowed to attach for
at least 15min. Fibers were then treated or not with 0.11μM rHsGal-1 and kept at 37°C until
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injury. At least three different myofibers in each dish were selected to be injured. The total
change in fluorescence intensity of FM™ 1-43 dye at the site of the wound for each time point
relative to the pre-injury fluorescent intensity was measured using ImageJ.163

2.2.9

Quantitative RT-PCR
Total RNA was isolated from 3 days differentiated A/J WT, A/J-/-, and A/J-/-treated with

0.11μM rHsGal-1 myotubes (n = 6 independent clonal lines for each treatment group) using
Quick-RNA™ Miniprep kit (ZYMO Research, Irvine, CA). Isolated RNA was reverse
transcribed using SuperScript™ IV VILO™ (ThermoFisher) following the manufacturer’s
instructions. Real-time analysis was performed on an Applied Biosystems® QuantStudio® 5
Real-Time PCR System using TaqMan® Fast Advanced Master Mix and TaqMan® Assays.
Relative gene expression levels and statistical significance were calculated by normalizing raw
Ct values to 18S, and then by using the ΔΔCt method with Applied Biosystems™ Relative
Quantitation Analysis Module software.168

2.2.10 Shotgun Proteomics
AJ WT, AJ-/-, and AJ-/- myotubes treated or not with 0.11 µM rHsGal-1 were prepared as
described in Wiśniewski et al169 with some alterations: Tris/HCl pH 8.5. Protein concentrations
were analyzed by PeirceTM BCA Protein assay kit (Thermo ScientificTM) following
manufacturer’s instructions. Protein digestion was initiated by adding PeirceTM MS grade trypsin
protease (Thermo SceintificTM cat. # 90058) to a 1:50µg ratio and incubated by shaking at 37˚C
overnight. Digestion was quenched by 100mM phenylmethanesulfylfluoride (PMSF, CAS # 32998-6) in ethanol (final concentration 1 mM) and centrifuged at 14,000g for 30min. The filtrate
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was transferred to Thermo FisherTM 11mm mass spectrometry vial. Samples went through
vacuum centrifugation and resuspended in orbitrap run buffer. Sample analyzation was
conducted on Thermo FisherTM Q-Exactive Obitrap. Gene Ontology analysis was processed
through Princeton University Lewis-Sanger Institute for Integrative Genomics Term Finder.170
Raw proteomic data can be found at doi: 10.25345/C5816M

2.2.11 Kinetic Proteomics
A/J-/- and A/J cells were cultured at 33°C and 10% CO2 in a growth media consisting of
20% FBS, DMEM Corning Ref #10-013CVR, 1%P/S, 2% Chicken Embryo Extract, 2uL/mL of
γ-IFN. A/J-/- and A/J cells were cultured at 37°C at 5% CO2 in a differentiation media
consisting of 5% Horse Serum, 1% P/S DMEM Corning Ref #10-013CVR. Cells were plated at
a density of 100,000 cells/mL in growth media until 80-90% confluency (1-2 days). Plates were
washed with PBS and changed into differentiation media, along with D2O and rHsGal-1
treatment if needed, as myotubes formed (3-4 days) with media and treatment being changed
every other day. Myotubes were scraped at 3, 5, 7, 14, and 28 days. Myotubes were added into
0.5mL of media and pelleted at 1200 rpm for 5 min, flash frozen and then kept at -20°C for one
day and then moved to -80°C storage. Myotubes and the isolated proteins were prepared as
described above for proteomic analysis. Turnover rates were calculated as previously described
in Price et al.57 Accession numbers were identified for each protein of interest, and their relative
abundance and turnover rates were aggregated. Turnover graphs were made under a singlepooled rise to plateau model.
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2.2.12 Statistical Analysis
Data analyses were completed by using Tukey’s multiple comparison test 1-way and 2way ANOVA, the Student’s t test, Welch’s, and Bartlett’s test through the GraphPad Prism
Software version 8.0. For membrane repair analysis, the data are conferred the averaged values
for all the myotubes used in the analysis, and the treatment at individual time points. P values are
indicated in the figure when statistical significance is determined for all groups as described in
the figure legends.

2.3

RESULTS

2.3.1

Production and Purification of rHsGal-1
Gal-1 induces skeletal muscle differentiation and decreases disease manifestation in

DMD. 95, 171 Exogenous Gal-1 may positively modulate different pathologies in LGMD2B. To
explore the effects of Gal-1 treatment in Dysf-deficient models, endotoxin-free rHsGal-1 was
produced using the pET29b(+) vector with a C-terminal 6X Histidine tag for easy detection
during purification and expression steps. Purification and detection analyses were made by total
protein stains and western blot (S2.1A-S2.1E Fig).

2.3.2

rHsGal-1 Increases Myogenic Potential in A/J-/- Myotubes.
The formation of myotubes is a multi-step process incorporating migration, adhesion, and

alignment, followed by formation of extracellular proteins that coordinate cellular stability.172
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Gal-1 expression levels during myoblast growth, differentiation and repair play a key role
in forming healthy skeletal muscle. The lack of Gal-1 leads to poor myotube formation and
delays in myoblast fusion.159, 173

Figure 2.1. rHsGal-1 increases myogenic regulatory factors in A/J-/- myotubes. A. Quantification of myogenin
after 72h treatment with varying concentrations of rHsGal-1. B. Western blot images of myogenin at different
rHsGal-1 treatments. C-F. Quantification of myogenic markers MHC(C), Pax7(D), MyoD (E), and Myf5 (F) in
A/J-/- myotubes after 72h treatment with 0.11µM rHsGal-1. G-H. Quantification of Gal-1(G) and His.H8(H)in
A/J-/- myotubes after 72h treatment with 0.11µM rHsGal-1. I. Western blot images of myogenic markers (Pax7,
Myf5, MyoD, and MHC) and of mouse Gal-1 and His Tagged rHsGal-1. J. RT-qPCR quantification of LGALS1
transcript between A/J WT, A/J -/- NT, and A/J -/- 0.11µM rHsGal-1 treated myotubes. p values are measured by
Tukey’s multiple comparison test and indicated by *p< 0.05, **p< 0.01, ****p< 0.0001 (n=3 for each group).
Error bars represent SEM.
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Myogenin is a muscle-specific transcription factor expressed by terminally differentiated
myotubes and is known to be decreased in immortalized A/J-/- myotubes.174 However, after a 72h
treatment with rHsGal-1, myogenin expression increased in A/J-/- myotubes (Fig 2.1 A & 2.1B).
To determine the most efficacious dose of rHsGal-1 required to increase myogenesis, A/J-/myoblasts either received no treatment (NT) or were treated with three concentrations of rHsGal1 for 72h post differentiation. When compared to NT myoblasts our results show a 4.74-, 9.35and 4.35-fold increase in myogenin with 0.054µM, 0.11µM, and 0.22µM rHsGal-1 treatment,
respectively (Fig 2.1 A & 2.1B.). To further investigate changes in myogenic potential, we
examined whole cell lysates and measured levels of early, mid, and late myogenic markers:
paired box protein 7 (Pax7), myogenic factor 5 (Myf5), myoblast determination protein (MyoD)
and myosin heavy chain (MHC) respectively, after treatment with a dose of 0.11µM rHsGal-1
(Fig 2.1 C-2.1F). Levels of early-stage markers decreased, while levels of late-stage markers
increased by 2.5-fold (MyoD) and 1.46-fold (MHC) when treated with 0.11µM rHsGal-1 (Fig
2.1 C-F & 2.1I). The removal of 0.11μM rHsGal-1 after a 10min treatment in A/J -/- myotubes
followed by 72 hours in differentiation media show no significant difference in Myf5 or MHC
expression when compared to NT (S2.2A-S2.2C Fig). The changes in myogenic transcription
factors were validated using immunofluorescent imaging. After 48h of differentiation, early
myotube populations with or without treatment were stained with a nuclear counterstain 4′,6Diamidino-2- Phenylindole, dihydrochloride (DAPI), an actin filament stain (Phalloidin) and
anti-Myf5. Images reveal that there was no Myf5 visible in WT or rHsGal-1 A/J-/- treated
myotubes, while Myf5 positive myoblasts are observed in A/J-/- NT (Fig 2.2C).
In order to show that rHsGal-1 treatment was the cause, we investigated transcript and
protein levels of Gal-1. RT-qPCR analysis revealed LGALS1 mRNA transcript levels were
39

doubled after a 72h 0.11µM rHsGal-1 treatment post differentiation (Fig 2.1J). Increases in
rHsGal-1, 6XHis-tag protein, and LGALS1 mRNA transcripts levels correlate with rHsGal-1
treatment and suggest a positive feedback loop that ultimately upregulates myogenic
transcription factors in diseased cells with a 72h treatment (Fig 2.1G-2.1J.). The levels of
6XHis-tag after 72 hours also indicate that the exogenous Gal-1 is internalized and stable within
cell culture.
Gal-1 knockout mice are reported to have decreased myofiber formation.159 We explored
the ability of rHsGal-1 to increase fusion capacity of A/J-/- myotubes by measuring fusion index,
alignment and size. Dysferlin-deficient myotubes were stained with Phalloidin or MHC and
DAPI to determine fusion index (Fig 2.2A &2.2B). Treatment with 0.11µM rHsGal-1 showed a
dramatic increase in number of nuclei per myotube (WT=11.4±0.59, NT=6.43±0.37, and
rHsGal-1=14.5±0.65) (Fig 2.2D) and average fusion index (WT=0.90±0.003, NT=0.85±0.007,
rHsGal-1=0.96± 0.004) (Fig 2.2E). Myotube and myofiber alignment have been shown to lead to
improved muscle development and strength.175 rHsGal-1 treatment led to significantly improved
myotube self-alignment compared to WT and NT myotubes (Fig 2.2F). Additionally, 0.11µM
rHsGal-1 treatment myotubes were 25% larger than WT and 35% larger than NT. These data
provide further evidence that rHsGal-1 treatment increases fusion capacity of A/J-/- myoblasts
towards formation of myotubes. (Fig 2.2G). An in vitro migration assay showed increased
myoblast migration and de novo myotube formation within the injured area. Our treatment
groups had the following average wound closure rates: NT=1.34 ± 0.12% area/hour, WT=1.69 ±
0.058% area/hour and 0.11µM rHsGal-1=1.77 ± 0.063% area/hour (Fig 2.2H). This set of
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experiments suggest that low doses 48h treatment of rHsGal-1 in an in vitro dysferlin-deficient
model may increase myogenic potential in myoblasts.

2.3.3

Increased rHsGal-1-mediated repair is dependent on the CRD of rHsGal-1 and

independent of Ca2+ in both dysferlin-deficient and non-diseased models.

The major pathological feature in LGMD2B is compromised membrane repair. To
explore the effectiveness of rHsGal-1 treatment on the membrane repair process, we employed a
membrane laser injury assay on dysferlin-deficient myotubes (myotubes defined as having >3
nuclei) in the presence of FM1-43, a lipophilic dye that fluoresces when bound to lipids. We
quantified the change in fluorescence after injury; cells with less dye entry indicate better
membrane repair. (Fig 2.3-A, Supplemental Video 1:
https://doi.org/10.1371/journal.pone.0238441.s006). These injuries were performed after
10min and 48h treatments to evaluate any time-dependencies. After laser injury, we quantified
changes in fluorescent intensity to measure effectiveness and kinetics of membrane repair. At
150s post-injury, A/J-/- myotubes treated with 0.11µM rHsGal-1 for 48h had 58% less dye entry
than NT, while a 10min treatment decreased final fluorescent intensity by 83% from NT. WT
had 90.1% less dye entry than NT. In comparing dysferlin-deficient treatments to WT cells, after
a 10min and 48h treatment A/J-/- cell only allowed 7% and 32% more dye than non-diseased
cells (Fig 2.3-B).
To determine the involvement of the Gal-1 carbohydrate recognition in repair capacity,
we performed a laser ablation assay in the presence of lactose or sucrose. The CRD of Gal-1 is
known to have a binding affinity for lactose whereas sucrose does not interact with the
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CRD.160,144 When A/J-/- myotubes were incubated with 20mM sucrose and 0.11µM rHsGal-1
10min prior to treatment, we observed an increase in membrane repair capacity consistent with
previous results. However, when rHsGal-1 CRD interactions were inhibited with lactose, we saw
no increase in membrane repair (Fig 2.3-C). We conclude that the CRD plays a crucial role in
the membrane repair mechanism of Gal-1.

Figure 2.2. rHsGal-1 treatment increases levels of fusion index and myotube maturity. A.
Representative images of A/J cells cultured and immunostained with Phalloidin (red) and DAPI (blue).
B. Representative images of A/J cells cultured and immunostained with MHC (red) and DAPI. C.
Representative images of A/J cells cultured and immunostained with Myf5 (green), Phalloidin, and
DAPI. D. Average number of nuclei per myotube compared between WT (n = 1608 nuclei, 187
myotubes, 10 fields), NT (n = 1587 nuclei, 215 myotubes, 9 fields), and 0.11 µM rHsGal-1 treated (n =
2476 nuclei, 166 myotubes, 13 fields) groups E. Fusion index between WT, NT, and 0.11µM rHsGal-1
treated myotube groups. F. Myotube alignment along the major axis compared between WT (n = 50
myotubes, 10 fields), NT (n = 49 myotubes, 9 fields) and 0.11 µM rHsGal-1 treated (n = 75 myotubes,
13 fields) myotubes. G. Minimum Feret’s diameter measurements between WT (n = 30 myotubes, 10
fields), NT (n = 34 myotubes, 9 fields), and 0.11µM rHsGal-1 treated (n = 36 myotubes, 13 fields)
myotubes. H. Rate of migration between WT, NT, and 0.11µM rHsGal-1 treated myoblast groups. p
values are measured by Tukey’s multiple comparison test and indicated by **p<0.01 and ****p<
0.0001. Error bars represent SEM. Scale bar = 100 μm
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Non-diseased models show that dysferlin-mediated repair is dependent on intrinsic Ca2+
signaling properties of dysferlin. 41, 132, 176 Therefore, dysferlin-deficient muscle fibers are
defective in many Ca2+ sensitive processes, including membrane repair. We conducted a group
of laser injury assays to determine the role of Ca2 in rHsGal-1 mediated. Dysferlin-deficient
myotubes treated with 0.11µM rHsGal-1 for 48h had a final change in fluorescent intensity 57%
lower than NT A/J-/- myotubes 150s post injury, independent of the presence of Ca2+ in their cell
media (S2.3A Fig). To better understand the Ca2+ independent therapeutic benefit of Gal-1 in
A/J-/- myotubes, we quantified final fluorescent intensity in the presence and absence of
extracellular (EGTA) and intracellular (BAPTA-AM) calcium chelators. We saw that rHsGal-1
treatment increases membrane repair and mitigates effects of dysferlin-deficiency in the presence
of both intracellular and extracellular calcium chelators (S2.3B & S2.3C Fig). Calcium imaging
using Fluo-4AM also revealed no increase in Ca2+ accumulation at site of injury in A/J -/- 0.11μM
rHsGal-1 treated and NT myotubes but did find an increase in Ca2+ accumulation at the site of
injury in A/J WT myotubes (S2.3D-S2.3G Fig). Next, we wanted to determine the positive
impact of rHsGal-1 on membrane repair in the presence of dysferlin through A/J+/+ WT
myotubes. We used EGTA to inhibit the normal, calcium-dependent function of dysferlin in WT
A/J+/+ myotubes. Our results showed no significant differences in membrane repair between nontreated A/J-/- and WT myotubes treated with EGTA. Although WT myotubes treated with EGTA
showed reduced repair due to lack of extracellular Ca2+, WT myotubes treated with
0.11μMrHsGal-1 plus EGTA showed a significant improvement in membrane repair similar to
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A/J-/- myotubes treated with 0.11μMrHsGal-1 (Fig 2.3D). Even when deprived of Ca2+, WT
cells treated with Gal-1 can alleviate repair defects due to lack of Ca2+.

Figure 2.3. rHsGal-1 treatment increases membrane repair capacity in A/J-/- and A/J+/+ myotubes dependent
on CRD activity. A. Representative images of FM 1-43 dye accumulation in NT and 48h 0.11μM rHsGal-1
treated A/J-/- myotubes after injury with UV laser. White arrows indicate site of injury. B. Quantification of the
change in fluorescent intensity inside A/J-/- myotubes following laser injury when treated with 0.11µM rHsGal1 for 10min and 48h compared to WT A/J+/+ and NT A/J-/- myotubes. C. Change in the fluorescent intensity in
0.11µM rHsGal-1 treated A/J-/- myotubes supplemented with lactose and sucrose compared to NT A/J-/myotubes. D. Change in the fluoresce intensity in 0.11µM rHsGal-1 treated A/J+/+ myotubes supplemented with
or without EGTA and rHsGal-1 compared to WT A/J+/+ and NT A/J-/- myotubes. Values were measured by
Tukey’s multiple comparison test and indicated by in B. ****p< 0.0001 A/J-/- NT vs A/J WT, ####p <0.0001
between A/J-/- NT vs A/J-/- 10min rHsGal-1, $$$$p<0.0001 between A/J-/- NT vs A/J-/- 48hr rHsGal-1, %p<0.05
between A/J-/- 48hr rHsGal-1 and A/J WT, and & p<0.05 between 10min and 48h. C. *p<0.05, **p<0.01,
***p<0.001. and ****p< 0.0001 between A/J-/- 0.11µM rHsGal-1 20mM sucrose vs. A/J-/- 0.11µM rHsGal-1
20mM lactose and A/J-/- NT. D. at least significance of **p<0.01 between A/J WT, AJ WT + EGTA + 0.11µM
rHsGal-1, and A/J-/- 0.11µM rHsGal-1 + EGTA vs. A/J-/- + EGTA and A/J WT + EGTA Scale bars = 50μm.
Error bars represent SEM. n ≥ 11 from 2 independent experiments for each group.
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2.3.4

Ex-vivo rHsGal-1 treatment increases membrane repair capacity in Dysf-/myofibers.
To verify in vitro myotube injury results, myofibers taken from Dysf-/- and Bla/J mice

were treated with 0.11μM rHsGal-1 for 2h prior to injury. Our results showed a 70% decrease in
final fluorescent intensity from NT in the Dysf-/- myofiber and a 57% decrease compared to NT
in the myofiber from the Bla/J mice. (Figs 2.4A-2.4C). Injured mice fibers taken from C57BL/6
(WT) mice treated with or without rHsGal-1 showed no significant differences in membrane
repair (Fig 2.4D). Additionally, we used EGTA to inhibit the normal, calcium-dependent
function of dysferlin in WT myofibers. When treated with EGTA, WT myofibers showed an
increased dye entry of 50% compared to WT without EGTA. However, WT myofibers treated
with EGTA plus 0.11μM rHsGal-1 were not significantly different from WT myofibers untreated
with EGTA or rHsGal-1 (Fig 2.4E). These (ex vivo) results give further weight to in vitro
myotube data.

2.3.5

rHsGal-1 localizes at the site of injury and sites of cellular fusion in dysferlindeficient myotubes.
We next examined temporal-spatial localization of rHsGal-1 during laser injury and

during myotube formation using AlexaFluor-647 conjugated rHsGal-1 (647rHsGal-1).
647rHsGal-1 localized on the membrane of myotubes after 10min incubation (Fig 2.5A).
However, after a 48h treatment there was minimal rHsGal-1 localized on the myotube membrane
and instead formed puncta within the cytosol (Fig 2.5B &5H), further indicating the stability of
the exogenous Gal-1 within these cells. After laser injury in the 48hr 647rHsGal-1 treated
myotubes, we observed 647rHsGal-1 concentrate at the site of injury. (Fig 2.5B). Confluent A/J45

/-

myoblasts treated with 647rHsGal-1 in differentiation media for 10min, 4h, 8h, 24h, and 48h

were imaged to resolve differences in membrane versus nuclear localization. 647rHsGal-1 in
confluent myoblasts treated for 10min accumulated on the membrane and intramembrane space
(Fig 2.5D). By 4h of treatment, 647rHsGal-1 dispersed throughout the intracellular and
extracellular space (Fig 2.5E). Beginning at 4h and 8h, 647rHsGal-1 appears to coalesce in the
shape of an extracellular lattice (Fig 2.5E & 2.5F, Supplemental Video 2:
https://doi.org/10.1371/journal.pone.0238441.s007

) which expands in both 24h and 48h images (Fig

2.5G & 2.5H). 48h post-treatment, we saw mature myotubes with intracellular rHsGal-1 and
extracellular lattice structures of rHsGal-1 at sites of cellular fusion (Fig 2.5G). Quantification of
our results show after 4h treatment 647rHsGal-1 is predominately located inside myoblasts but
by 8h and beyond most of the rHsGal-1 is found outside the cells (Fig 2.5C). Additionally, we
saw 647rHsGal-1 encapsulated in lipid layers, suggesting the formation of vesicles (Fig 2.5I and
Supplemental Video 3: https://doi.org/10.1371/journal.pone.0238441.s008 ).
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Figure 2.4. rHsGal-1 treatment positively effects sarcolemma and membrane repair in a Ca2+ depleted
environment. A. Representative images at time points 0s, 30s, 60s, 90s of FM1-43 dye accumulation in Bla/J
mouse fibers upon laser injury with a 405nm laser. White arrows indicate site of injury. B. Quantification of
the total change of fluorescence in Bla/J myofibers. C. Quantification of the total change of fluorescence in
Dysf-/- myofibers post injury. D. Quantification of the change in fluorescence in C57BL/6(WT) myofibers
after treatment with or without rHsGal-1. E. Quantification of the change in fluorescence in C57BL/6(WT)
myofibers after treatment with or without EGTA and rHsGal-1. p values were measured by Tukey’s multiple
comparison test and indicated by *p< 0.05, **p< 0.01, and ***p< 0.001. Scale bars = 50μm. Error bars
represent SEM. n≥ 15 myofibers per condition.
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Figure 2.5. rHsGal-1 localizes at the site of injury and is found in intra and
extracellular spaces. A-B. Representative images of laser ablation assay with labeled
647rHsGal-1 (green) and FM1-43 Dye (red) with treatment time of 10min(A) and 48h(B).
White arrows indicate site of injury. C. Quantification of the average ratio of corrected
total cell 647rHsGal-1 fluorescence between inside and outside of the cell. D-I. Confocal
images of A/J -/- myoblasts/myotubes treated and differentiated with 0.11µM rHsGal-1 at
varying time points: 10min (D), 4h (E), 8h (F), 24h (G), 48h (H), with labeled rHsGal1(647rHsGal-1) (green) showing nucleus (blue) and membrane (red) identifying critical
structures pertaining to rHsGal-1 location. 1 and 2 represents vesicles. localization (I).
Zoom: rHsGal-1 encapsulated in vesicles.
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2.3.6

Proteomic analysis shows rHsGal-1 increased expression of muscle development
proteins in dysferlin-deficient myotubes.
Lysates from WT, A/J-/- NT and A/J-/- rHsGal-1 treated myotubes were analyzed using

shotgun proteomics and Gene Ontology Slim (GO-Slim) bioinformatics.177 A heat map was
generated using the top 20 upregulated and 20 downregulated proteins relative to average protein
expression levels from all treatment groups (Fig 2.6A). Results showed an overlap of
upregulated protein in the WT and rHsGal-1 treatment group compared to average expression
(Fig 2.6A). We performed a GO-Slim analysis on all peptides with a fold change greater than 2
from NT to examine differences between NT and rHsGal-1 treatment proteome. Within this
group, we examined the following GO-terms based on LGMD2B pathology that returned to WT
levels after a 48h treatment: 55% involved cellular component organization (GO: 0016043),
27.4% in cell and muscle differentiation (GO: 0030154 and GO:0043592), 13% in cell migration
(GO: 0016477), and 4.3% inflammatory response (GO: 0006954) (Fig 2.6B & 2.6C).
The annexin superfamily of proteins (ANXA) is important in many myogenic processes.178,139,59
When we compared the proteomic results of WT and 0.11µM rHsGal-1 treated myotubes using
their fold changes from the NT myotubes, ANXA1, ANXA2, ANXA4, and ANXA6 were identified
as being in the top 20 upregulated proteins with treatment (Fig 2.6A). The increased protein
expression was confirmed via western blot analysis for ANXA1 and ANXA6 (Fig 2.6D &
2.5GG). This increase was not seen in WT cells treated with rHsGal-1 (S2.4 Fig). Proteomics
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analysis supports the results that rHsGal-1 is a multifunctional protein capable of improving
muscle development in LGMD2B.
Lysates from WT, A/J-/- NT, and rHsGal-1 treated myotubes were also analyzed using
kinetic proteomics to determine protein turnover rate. Deuterium incorporation was measured at
day 0, 3, 5, and 28 to determine the fraction of each protein that was newly synthesized. ANXA1
and ANXA6 from rHs-Gal-1 treated myotubes had increased turnover rate as compared to NT

Figure 2.6. Shotgun proteomic analyses (MS/MS) of AJ WT, AJ-/- NT and 0.11 μM rHsGal-1 treated myotubes.
A. Heatmap of top 20 and bottom 20 expressed proteins for WT myotubes based on Log2 fold change (FC) from the
mean value all conditions. Box denotes cluster of proteins that had similar FC values between WT and rHsGal-1
treatment. B. GO-Term Slim analysis of rescued proteins. C. Relative number of proteins found in the selected GOTerms(B). D. Log2FC of Annexin family proteins (calculated based on WT and Gal-1 FC from NT). E. Quantification
of ANXA6 after 48h differentiation in WT, NT, and 0.11μM rHsGal-1 treated myotubes. F. Quantification of ANXA1
after 48h in WT, NT, and 0.11μM rHsGal-1 treated myotubes. G. Western blot images of ANXA1 and ANXA6. p values
were measured by 2-way ANOVA multiple comparison test and indicated by *p< 0.05, **p< 0.01, and ***p< 0.001.
Error bars represent SEM. n= 3. All proteins were preselected based on protein ID significance values of ≥20% (p≤
0.01, FDR≤0.05).
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myotubes. Together, the upregulation and increased turnover rate shows that ANXA1 and
ANXA6 are synthesized more with rHs-Gal-1 treatment (S2.5 Fig).

2.4

Discussion
Current therapeutic options for LGMD2B are chiefly palliative in nature and do not

present a significant quality of life benefit sought for by patients and their families. Steroid
treatment to reduce chronic inflammation is negatively correlated with patient muscle strength
and poses significant negative side effects.179 Therefore, the need for developing an effective
long-term treatment is imperative. Prior research using DMD murine models identified Gal-1 as
an efficacious treatment in reducing disease symptoms.95 Although DMD and LGMD2B have
different genetic etiologies, both diseases converge in their disease pathologies, leading to
decreased myogenic potential and aberrant repair. Here, we demonstrate that the ability of
rHsGal-1 to improve myogenic factors and membrane repair reflects its therapeutic potential to
decrease disease pathologies in LGMD2B.
Dysferlin-deficient muscle cells show a marked decrease in myogenic potential.180, 181
After treatment with rHsGal-1, the expression of myogenic transcription factors reveals that
dysferlin-deficient cells are committing to a myogenic lineage and maturing faster than nontreated dysferlin-deficient cells. The removal of treatment after a 10min rHsGal-1 followed by
72h differentiation was not sufficient to induce differences in myogenic, however, continuous
72h rHsGal-1 treatment coincided with increases in middle and late-stage markers. These results
coupled with the formation of large multinucleated myotubes suggest that Gal-1 may help
satellite cell commitment (Fig 2.2A, 2.2B, & S2.2 Fig). During in vivo muscle development,
self-alignment of myotubes during myogenesis is crucial to form healthy myofibers. Self51

alignment is increased due to Gal-1 treatment in myotubes, indicating that an in vivo Gal-1
treatment has the potential for similar results (Fig 2.2F). We observed a concurrent upregulation
of LGALS1 transcript along with an increase in late-stage myogenic markers, suggesting a
positive feedback loop with a 72h rHsGal-1 treatment, confirming the result seen in other models
(Figs 2.1C, 2.1E, 2.1I, & 2.1J).171, 182 One possible explanation for upregulated Gal-1 transcript
is that increases in MyoD is known to robustly activate gene transcription possibly leading to
eventual downstream Gal-1 transcription.183
Since exogenous addition of Gal-1 does not increase proliferation,152 our findings
suggest that Gal-1 treatment increased the rate of myogenesis in treated cells relative to their
non-treated counterparts leading to increased myogenic fusion (Fig 2.1 & 2.2). In vitro
proteomic analysis further supports these findings through the upregulated proteins involved in
muscle cell differentiation, cellular differentiation, cell migration, and inflammatory response
(Fig 2.6).
Ca2+ sensitive C2 domains of dysferlin aid in plasma membrane resealing, a necessary
process in myogenesis and wound healing.56 In dysferlin-deficient myofibers and cells, this
process is compromised, which leads to diminished reseal capacity after injury, perpetuating
LGMD2B disease pathology.41, 184, 185 Kinetic laser injury results show that a 10min and 48h
treatment improves membrane sealing; interestingly, the 10min treatment provided optimal
membrane repair without upregulating myogenesis (Fig 2.3B, S2.2A-S2.2C Fig). However, this
implies that rHsGal-1 induced improvement in myogenic potential alone cannot be responsible
for the dramatic improvements in membrane sealing for this immediate result. Mechanical
stabilization on the membrane due through the CRD of Gal-1 with known glycosylated
membrane bound, EMC or yet to identified ligand could account for this action.
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Differences in Ca2+ involvement, along with temporal-spatial localization, helps narrow
down possible mechanistic pathways responsible for observed increases in repair in a LGMD2B
system. Ex-vivo results suggest that rHsGal-1 treatment improves membrane repair capacity in
two different dysferlin-deficient strains of mice. Moreover, rHsgal-1 will not alter normal
membrane repair functionality at this dose and is independent of Ca2+ as we showed in A/J-/- and
A/J+/+ myotubes (Fig 2.3 & 2.4). One hypothesis that may offer explanation towards increase
membrane repair capacity independent of Ca2+ is rHsGal-1 treatment upregulates crucial
membrane repair proteins such as ANXA1 and ANXA6 (Fig 2.6E & 2.6G). The upregulation of
ANXA1 and ANXA6 could also be attributed to differences in the rate of myogenesis since they
are upregulated with differentiation.
The annexins regulate lipid binding, cytoskeletal reorganization, and muscle membrane
repair cap formation.132, 139 ANXA1 and ANXA6 have been observed to be involved in vesicle
fusion, membrane resealing, muscle cell migration, and differentiation.139, 143 Overexpression of
ANXA6 promotes external blebbing and addition of exogenous ANXA6 increases membrane
repair.59 Our results show that rHsGal-1 treatment resulted in a significant increase of ANXA6
from NT in dysferlin-deficiency (Fig 2.6). Injury repair kinetics coupled with visualization of
647rHsGal-1 treatments show that Gal-1 accumulated at the site of laser injury in dysferlindeficient myotubes. It is unlikely that these increased levels of ANXA are due to overall
increased differentiation in LGMD2B models. Previous research has shown that exogenous Gal1 treatment of both C2C12 cells and human fetal mesenchymal stem cells increase myogenic
regulatory factors.186 The lack of increase in ANXA levels in WT myotubes with treatment, lead
us to conclude that this may be a specific to dysferlin-deficiency or an undefined interaction of
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ANXAs. This merits further inquiry to discover the mechanism responsible for Gal-1
interactions with specific substrates resulting in increased repair.
Our results indicate that the CRD of rHsGal-1 is an active structure required for
therapeutic effect of Gal-1 in increasing membrane repair capacity (Fig 2.3). We believe the
CRD provides mechanical stabilization to the membrane, aiding other cellular repair machinery
to effectively mitigate damage and enhance repair. Mechanical stabilization also explains
calcium-independent action for membrane repair and the difference in membrane repair seen at
10 min versus 48 hrs.
Healthy myogenic membranes after injury have a transient period of mobility and return
to a state of low mobility.109, 187, 188 One explanation for membrane destabilization and lack of
proper repair in dysferlinopathy is an increase in lipid mobility.109 Localization of labeled
rHsGal-1 after 10min of treatment prior to injury is chiefly on the plasma membrane, whereas
after a 48h treatment it appears as intracellular puncta, membrane bound puncta, and in lattice
formation (Fig 2.5A & 2.5B). A previous study shows that after 1h incubation Gal-1 localizes
primarily intracellularly, which was confirmed in our 4h 647rHsGal-1 images and quantification
(Fig 2.5 C).189 The greater accumulation of Gal-1 on the plasma membrane and increased repair
capacity at 10min provides evidence that treatment may stabilize membrane associated proteins
involved in repair enough to overcome the lack of dysferlin. Temporal-spatial images and
fluorescent quantification provide evidence that by 8h, lattice structures are forming which may
further explain enhanced membrane stability and changes in protein interactions in LGMD2B
(Fig 2.5C).190, 191 Furthermore, Gal-1 induced lattice formations appears to correlate with sites of
cellular fusion (Fig 2.5, S2.3 Fig, S2.2 Video). Future studies need to answer questions about
localization and identification of rHsGal1 endogenous interactors or ligands at the sites of injury.
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Cumulative results from this study provide evidence that rHsGal-1 may be a feasible
protein therapeutic for LGMD2B by orchestrating a variety of changes that overcome intrinsic
defects in myogenic functions. Increased connectivity observed in labeled rHsGal-1 may result
in increased cellular signaling suggesting a potential mechanism for Gal-1 induced membrane
repair that needs further investigation. Previous findings indicate localization of Gal-1 in the
ECM.81 The appearance of increased deposition of labeled rHsGal-1 in the extracellular space
herein indicates that Gal-1 may increase skeletal muscle integrity in animal models of
dysferlinopathy (Fig 2.5). These cumulative results support the hypothesis that the CRD
mechanistically binds glycosylated membrane associated proteins, providing stability and
overcoming inherent membrane destabilization due to lack of dysferlin. Although questions
remain about the nature of rHsGal-1 therapeutic mechanisms and systematic effects in more
complex models of LGMD2B, these results provide evidence that Gal-1 is a viable therapeutic
candidate in muscle diseases. The following chapter will add to the therapeutic power of Gal-1,
by exploring Gal-1s immuno-regulatory and anti-inflammatory functions within LGMD2B
models.
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2.5

Supplemental Material

2.5.1

Supplemental Figure S2.1

S2.1Fig. Construct and purification of rHsGal-1. A. rHsGal-1
construct which was inserted into pET-29b (+) vector. B. Coomassie
Blue Stain of Gal-1. C. Ponceau S stain of Gal-1. D. Western blot image
of Anti-Gal-1 at decreasing dosages. E. Western blot image of Anti-6xHis at decreasing dosages.

2.5.2

Supplemental Figure S2.2

S2.2.Fig. 10min treatment with rHsGal-1 does not influence myogenesis. A. Western blot
images of NT and 10min 0.11uM rHsGal-1 treated cells. B. Quantification of MYF5 expression.
C. Quantification of MHC expression.
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2.5.3

Supplemental Figure S2.3

S2.3 Fig. rHsGal-1 treatment increases membrane repair in A/J-/- myotubes independent of calcium. A.
Quantification of the change in fluorescent intensity in 0.11μM rHsGal-1 treated A/J-/- myotube with or without
extracellular Ca2+ compared to NT myotubes supplemented or not with extracellular Ca2+. B. Quantification of the
change in fluorescent intensity in 0.11μM rHsGal-1 treated A/J-/- myotube with or without EGTA compared to
NT. C. Quantification of the change in fluorescent intensity in 0.11μM rHsGal-1 treated A/J-/- myotubes with or
without BAPTA-AM compared to NT. D. Representative images of NT and rHsGal-1 treated myotubes, with FM4464 and Fluo-4AM, pre-injury, 1s after injury, and 90s after injury. White arrows indicate site of injury. E.
Quantification of Fluo-4 fluorescence within myotubes pre-injury, 1s after injury, and 90s after injury. F.
Representative images of A/J WT myotubes with FM4-64 and Fluo-4AM pre-injury and 1s, 35s, and 90s after
injury. White arrows indicate site of injury. G. Quantification of change in Fluo-4AM fluorescence at injury. p
values were measured by 2-way ANOVA multiple comparison test and indicated by *p< 0.05, **p< 0.01, ***p<
0.001, and ****p< 0.0001. Additionally, $p<.05, and $$p<.01 between NT and 0.11μM rHsGal-1 0mM Ca2+
treatment. Error bars represent SEM. n > 5 for each group.
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2.5.4

Supplemental Figure S2.4

S2.4 Fig. rHsGal-1 does not affect WT levels of ANXA1/6. A. Western blot images of A/J+/+ cells after no
treatment (NT) or 48hr treatment with 0.11uM rHsGal-1. B. Quantification of ANXA6 expression. C. Quantification
of ANAX1 expression
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2.5.5

Supplemental Figure S2.5

S2.5 Fig. rHsGal-1 increases turnover rates of ANXA1 and ANXA6 compared to non- treated A/J-/- myotubes. A-C. ANXA6
kinetic graphs quantifying the fraction of ANXA6 peptides incorporating D2O over time in days. D-F. ANXA1 kinetic graphs
quantifying the fraction of ANXA1 peptides incorporating D2O over time in days. G. table with ANXA1 area (relative
abundance) and turnover rate and its standard deviation. H. table with ANXA6 area (relative abundance) and turnover rate and
its standard deviation.
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Abstract
Galectin-1 is a small (14.5 kDa) multifunctional protein with cell-cell and cell-ECM
adhesion due to interactions with the carbohydrate recognition domain (CRD). In two types of
muscular dystrophies, this lectin protein has shown therapeutic properties, including positive
regulation of skeletal muscle differentiation and regeneration. Both Duchenne and Limb-Girdle
Muscular Dystrophy 2B (LGMD2B) are subtypes of muscular dystrophies characterized by
deficient membrane repair, muscle weakness, and eventual loss of ambulation. This chapter
explains confocal techniques such as laser injury, calcium imaging, and galectin-1 localization to
examine the effects of galectin-1 on membrane repair in injured LGMD2B models.

Key Words: Galectin-1, muscular dystrophy, LGMD2B, sarcolemma, membrane repair,
localization, protein labeling.

3.1 Introduction
Muscular dystrophies comprise a heterogeneous group of genetic diseases, some of which
have compromised sarcolemma stability, decreased muscle strength, and aberrant membrane
repair. Despite the fact that each type of muscular dystrophy has its own unique etiology, many
forms of muscular dystrophies, such as Limb-Girdle Muscular Dystrophy 2B (LGMD2B) and
Duchenne Muscular Dystrophy display compromised sarcolemma repair. The incidence of
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LGMD2B disease ranges from 1:1,300 to 1: 200,000, with certain geographic locations and
ethnic population more heavily impacted than others. Human patient, mouse, and cell models of
LGMD2B have mutations in the DYSF gene, resulting in non-functional dysferlin, a key
membrane protein. People with LGMD2B experience decreased mobility, chronic inflammation,
and fat infiltration into muscle groups, leading to a diminished quality of life.
The protein Galectin-1 (Gal-1) is expressed intra- and extra-cellularly, leading to positive
regulation in regeneration, neurodegeneration, and inflammatory diseases, including muscular
dystrophies 81. Gal-1 has been shown to increase myogenic potential, the process of muscle
growth, and repair capability in in vitro and ex-vivo models of LGMD2B (Fig. 3.1 & 3.2) 42.
Additionally, Van Ry et.al 95 showed that exogenous treatment with Gal-1 improved sarcolemma
stability and disease manifestations in Duchenne Muscular Dystrophy 191.
Since sarcolemma repair is a vital part of cell homeostasis, our research uncovers
biochemical characteristics of Gal-1 and how it functions to reduce muscle disease pathologies.
Membrane stability and repair capacity of cells and tissues were evaluated through modified
FRAP assays. This assay allows for precise, reproducible injuries to membranes through ablation
by a UV laser pulse. When used in skeletal muscle cells, this technique is meant to simulate
micro-injuries that occur during normal muscle use. Furthermore, this assay allows for the
concurrent examination of any fluorescently labelled protein to examine co-localization and
movement during injury events. We have used these methods to discover the therapeutic effect
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Gal-1 has in membrane Repair. The versatility of this technique allows the combined use of in
vitro or ex vivo (explants) with drugs along with real-time visualization.
The carbohydrate recognition domain (CRD) of Gal-1 is necessary for improved
membrane resealing using dysferlin-deficient myotubes. Functionally, the promiscuous nature of
the CRD allows Gal-1 to have many binding partners and affect several different cellular
processes. In order to better understand the importance of the CRD during membrane repair, we
inhibited activity of the CRD with lactose, which is a known antagonist of this domain. This
prevented binding of Gal-1 to other molecules via the CRD. We found that the CRD of Gal-1 is
essential for membrane repair, as there was no improvement in membrane repair after the CRD
was inhibited 42.
Another necessary component of normal muscle repair is calcium regulation 59, 129, 130. To
understand the dependence of Gal-1’s on calcium during membrane repair in LGMD2B models,
we performed laser ablations in the presence and absence of calcium, calcium chelators, and
labelled calcium. Our results showed that Gal-1 improves membrane repair capability in a
calcium-independent manner 42. Combined with co-localization imaging, this suggests that Gal-1
stabilizes the membrane through interactions with the CRD, independent of calcium.
In this chapter, we explain how to use labeled and unlabeled Gal-1 with varying
conditions for live confocal laser injury. These techniques were employed to evaluate therapeutic
benefits of Gal-1 through membrane injury assays. While we explain how to injure muscle
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specifically, the assay can be adapted to look at membrane repair in a variety of cell types with
or without the use of pharmacological agents to define unknown interactions.

A

B

Figure 3.1. Galectin-1 as Potential Therapeutic for LGMD2B. A Highlighted-regions show the
muscles affected by LGMD2B. B Graphical representation of how Gal-1 helps increase membrane
repair in LGMD2B.
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B

C

D

E

F

Figure 3.2: Laser Injury Workflow. A A/J-/- myoblasts are differentiated to form. B myotubes. C BLA/J mice
are processed to yield D myofibers. E The myotubes or myofibers are injured via laser on a confocal
microscope, causing internal fluorescence change as dye enters the cell. F. The fluorescence change is
quantified using ImageJ.
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3.2. Materials

3.2.1

Production and purification of recombinant Human Galectin-1 (Gal-1)

1. Human Galectin-1 gblock LGALS1 (Integrated DNA Technologies, Coralville, IA)
2. pET29b (+) vector (Novagen, Millipore Sigma)
3. NEBuilder® HiFi DNA Assembly Cloning Kit (E552OS New England Biolabs (NEB),
Ipswich, MA)
4. E.Z.N.A.® Plasmid DNA Mini Kit I protocol (Omega Bio-Tek, Inc. Norcross, GA)
5. BL21 (DE3) competent E. coli cells (High Efficiency, NEB # C2527H)
6. Phosphate Buffered Saline [PBS] (Gibco)
7. Sepharose 4B (Sigma-Aldrich)
8. Isopropyl β-D-1 –thiogalactopyranoside (IPTG) (Promega).
9. Lactose (Alfa-Aesar)
10. Β-mercaptoethanol (βME)
11. Complete Mini EDTA-free Protease Inhibitor Cocktail tablets (Thermo Fisher).
12. Lysozyme (Sigma Aldrich)
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13. Universal Nuclease for Cell Lysis, Thermo Scientific, Pierce Universal Nuclease for Cell
Lysis (Thermo Scientific)
14. Sodium bicarbonate, Na2CO3 (Macron Fine Chemicals)
15. Divinyl sulfone (Sigma Adlrich)
16. Sodium azide (Thermo Scientific)
17. Tris Base
18. Glycine
19. Sodium Dodecyl Sulfate
20. Loading buffer (Thermo Scientific)
21. 30% Bis-acrylamide (Alfa Aesar)
22. Molecular Weight Marker: BLUEstainTM 2 protein ladder (Gold Bio)
23. 1.7 mL snap cap microcentrifuge tube
24. 2 L Erlenmeyer flask
25. 1 L centrifuge bottles
26. Pierce™ Coomassie (Bradford) Protein Assay Kit (ThermoScientific)
27. Lennox broth (LB) powder
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Special Equipment
1. Centrifuge (Eppendorf)
2. Sonicator (BRANSON Digital Sonifier)
3. Gel apparatus including voltage source (BioRad)
4. Imaging (Licor Odyssey® CLx Imaging System)
Buffers
1. Wash Buffer (1L) = 1x PBS with 14 mM βME
2. Lysis Buffer (for 1L of culture) = Wash Buffer including 1 Complete Mini EDTA-free
Protease Inhibitor cocktail tablet, Lysozyme (1mg), Pierce Universal Nuclease for Cell
Lysis (Thermo Scientific) (100 µL of nuclease at a concentration of 0.1 µL/mL).
3. Elution Buffer (1L) = 1x PBS with 14 mM βME and 100 mM Lactose (36 g)
4. Column Storage Buffer (total volume 500 mL) = 1x PBS w/0.02% Sodium Azide, 14
mM βME
5. 1x Electrophoresis Buffer = 3 g Tris Base, 14.4 g Glycine and 1 g Sodium Dodecyl
Sulfate in total volume of 1 L dH2O
6. Destain Solution = 40% Methanol and 10% Glacial Acetic Acid in dH2O
Separation
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1. PD10 column (GE Healthcare)
2. PBS (Gibco)
3. Econo-Column® Chromatography Columns, 1.5 × 50 cm (Bio-Rad)
4. Sand, quartz (Thermo Scientific)
5. Lactose (Alfa Easar)
6. Β-mercaptoethanol (Fisher)
7. Sepharose 4B (Sigma-Aldrich)

3.2.2

H2K A/J-/- and H2K A/J+/+ cell culture

1. Immortalized murine myoblasts H2K A/J-/-, [A/J-/-], (Clone #13-1,10/28/09) and H2K A/J
WT, [WT], (Clone #16, 6/9.2010) (Purchased from Center for Genetic Medicine
Research, Washington, DC)
2. Glass-bottomed, collagen coated dishes sterilized with gamma-irradiation (MatTek,
Ashland, MA)
3. T-175 Flasks (Sarsted)
4. Counting slides dual chambers for cell counter (BioRad)
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5. Growth Media [DMEM (4500 mg/L glucose, 4 mM L-Glutamine, 110 mg/L Pyruvate)
(Gibco), 20% HI-FBS (Invitrogen), 2% Chick embryo extract (US Biological Life
Sciences), 2% L-glutamine (Sigma), 1% penicillin/streptomycin]
6. BSA 10% Stock Solution (Invitrogen)
7. Filter 0.22 μm (Fisher)
8. Differentiation Media [ DMEM (4500 mg/L glucose, 4 mM L-Glutamine, 110 mg/L
Pyruvate) (Gibco), Horse Serum (Invitrogen), 1% penicillin/streptomycin]
9. Interferon gamma (Gibco)
10. PBS (Thermo Fisher)
11. Penicillin/Streptomycin (CAISSON)
12. Trypsin EDTA (Gibco)

3.2.3

Calcium Dependency on membrane repair

1. H2K A/J-/- and H2K A/J+/+ cells
2. Gal-1 (0.11μM, diluted in PBS)
3. 35mm Glass Bottom Microwell Dishes (Mat Tek, Ashland, MA)
4. 1 mM Ca2+ (as CaCl2)
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5.

1 µM intracellular (1,2-Bis(2-aminophenoxy) Ethane-N, N, N′, N′-tetraacetic acid
tetrakis (acetoxymethyl ester); (BAPTA-AM) (EMD Millipore)

6. DMSO (EMD Millipore)
7. 1 µM (ethylene glycol-bis (β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; (EGTA)
(Acros Organics)
8. 2.5 µM FM™ 1-43 dye (N-(3-Triethylammoniumpropyl)-4-(4-(Dibutylamino) Styryl)
Pyridinium Dibromide)3,5. (ThermoScientific)
9. Fluo-4 AM Cell Permeant (Fisher Scientific)
10. TCS SP2 two-photon confocal scanning microscope (Leica)
11. 405 nm UV laser at 100% power on a HCX PL APO CS 63.0 x 1.40 oil-objective lens
[TCS SP2 two-photon confocal scanning microscope (Leica)]

3.2.4

Activity of Carbohydrate Recognition Domain in Membrane Repair.

1. H2k A/J-/- cells
2. Gal-1 (0.11μM, diluted in PBS)
3. 35mm Glass Bottom Microwell Dishes (MatTek,)
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4. 2.5 µM FM™ 1-43 dye (N-(3-Triethylammoniumpropyl)-4-(4-(Dibutylamino) Styryl)
Pyridinium Dibromide)3,5 (ThermoScientific)
5. TCS SP2 two-photon confocal scanning microscope (Leica)
6. 405nm UV laser (TCS SP2 two-photon confocal scanning microscope Leica)
7. HCX PL APO CS 63.0 × 1.40 oil-objective lens
8. Lactose (20mM) (Alfa Aesar) in PBS
9. Sucrose (20mM) (Carolina Biological) in PBS

3.2.5 Labeling Galectin-1 through primary amines
1. H2k A/J-/- cells
2. Gal-1 (0.11μM, diluted in PBS)
3. Alexa Fluor 647 (Protein labeling kit (Molecular Probes))
4. Wash buffer, 14 mM β-mercaptoethanol in PBS
5. PD-10 Desalting Columns (GE Healthcare)
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3.2.6

Confocal Visualization of Labeled Galectin-1

1. CellBrite Green Cytoplasmic Dye (Biotium)
2. Hoechst 33342 (Thermo Scientific)
3. EZBlockTM buffer (Biovision)
4. 4% paraformaldehyde (PFA) (Thermo Fisher Scientific)
5. ProLongTM Diamond Antifade Mountant (Invitrogen)
6. 18 mm circle glass coverslip
7. Clear nail polish (Sinful Colors Professional Polish)
8. Confocal Wash Buffer: 10% Sea Blocking Buffer (Thermo), 90% PBST

3.2.7

Muscle Fiber Isolation

1. 12-well plate (Grenier Bio-One)
2. C57B6 and Dysf-/- (B6.129-Dysftm1Kcam/J) mice (Jackson Laboratories)
3. Mouse Surgical Kit (Kent Scientific Corporation)
4. 35mm Glass Bottom Microwell Dishes (Mat Tek)
5. 0.11μM Gal-1 (diluted in PBS)
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6. FM™ 1-43 dye (Invitrogen)
7. Digestion solution: Collagenase Type 2, (40mg/mL, diluted in DMEM) (Gibco)
8. DMEM (DMEM (4500 mg/L glucose, 4 mM L-Glutamine, 110 mg/L Pyruvate) (Gibco),
9. PBS (Gibco)

3.3 Methods
3.3.1
1.

Production of recombinant Human Galectin-1
Linearize the pET-29b (+) vector by mixing the following: 20 µL of the vector at 140
ng/µL, 22.5 µL of ultrapure water, and 5 µL of 10X CutSmart Buffer.

2.

Digest the mixture by adding 1.5 µL of NdeI restriction enzyme, then incubating for 8
hours at 37 °C. After 8 hours, add to the mixture 1.0 µL of NdeI restriction enzyme and
continue incubating overnight at 37 °C (See Note 1).

3.

After 24h, complete the digestion by heating the mixture at 65 °C for 20 minutes (See
Note 2).

4.

Re-suspend the gBlock gene fragment LGALS1 by centrifuging the tube for 3-5 sec at a
minimum of 3000×g. After centrifugation, add 50 µL of TE buffer to reach a final
concentration of 10 ng/mL.
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5.

Prepare the assembly process. Mix the assembly, restriction enzyme-digested vector,
and the gBlock LGALS1 insert by setting up the following reaction on ice: 1:2 vector:
insert DNA (molar ratio), 10 µL of NEB Builder HiFi DNA assembly master mix, and 7
µL of deionized water. Incubate the sample in the thermocycler at 50 °C for 20 minutes
(See Note 3).

6.

Confirm the transformation process via agarose gel electrophoresis. Prepare a 1%
agarose gel and run ~5.0 µL of the digested vector mixed with 1X SDS loading dye and
~5.0 µL of the linearized vector in separate wells.

7.

Transform the cloned vector into BL21(DE3) competent E. coli cells following the NEB
(C2527) heat-shock protocol (See Note 4).

8.

Place and spread ~50-100 µL of transformed bacteria onto an agar plate previously
prepared with kanamycin (50 µg/mL) and incubate overnight at 37 °C.

9.

Select a colony from the agar plate and grow overnight in LB broth. Lyse the bacteria
and purify the pET 29b (+) plasmid DNA by using a Mini Kit Protocol and confirm the
sequence (See Note 5 and Note 6).

10. Prepare the starter culture by selecting a colony and placing in sterile 10 mL LB
broth/Kanamycin (50 µg/mL) overnight at 37 °C with shaking at 250 rpm (See Note 7).
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11. Take 10mL of the starter culture and pour into 1 L of autoclaved LB broth/ kanamycin
(50 µg/mL) and place it in a shaker incubator set at 37 °C and 250 rpm.
12. Check the optical density at 600nm (OD600) of the culture every 20-30 min using a
spectrophotometer until the cultures reach an OD of 0.5-0.6 and induce the Gal-1
expression by using 0.1mM of IPTG. Continue the IPTG induction overnight at 30 °C
and 250 rpm.
13. Next day, collect bacteria in a 1L plastic centrifuge container and centrifuge down to a
pellet at 14,000 RCF for 30 min at 4 °C.
14. Discard the supernatant without disturbing the bacteria pellet (See Note 8).
15. Add 10 mL of lysis buffer to the bottle and re-suspend the pellet until homogeneous and
let the homogeneous mixture sit at room temperature for 30 min.
16. Pour the re-suspended sample in a 150 mL beaker. Place the beaker on ice and sonicate
5s on, 5s off at 80% amplitude for 5min, or until the sample appears cloudy.
17. After sonification, add Protease Inhibitor (use 100X protease inhibitor, dilute to 1X in
solution).
18. Spin the sonicated lysate at 13,000 RCF for 30-45 min at 4 °C.
19. Remove the supernatant without disturbing the pellet. Save the supernatant on ice or
store at -20 °C.
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3.3.2

Purification of recombinant Human Galectin-1

1. Prepare a lactosyl-Sepharose column by placing 100 mL of Sepharose 4B into a Buchner
funnel containing filter paper under vacuum.
2. Wash the Sepharose with 0.5 M Na2CO3 until pH reaches 11 (See Note 9).
3. Transfer the dried Sepharose into a 250 mL beaker and add 100 mL of 0.5 M Na2CO3 to
resuspend.
4. Add 10 mL of divinylsulfone into the beaker slowly (2 mL aliquots over 15 min). The
reaction mixture should turn slightly brown. Add a magnetic stir bar and stir lightly for
70 min (See Note 10).
5. Transfer reaction mixture to the Buchner funnel and wash with 100 mL of 0.5 M
Na2CO3.
6. Transfer the dried and activated Sepharose into a beaker and add 100 mL of 0.5 M
Na2CO3 containing 10% lactose (w/v).
7. Add the magnetic stir bar and gently stir for 15hrs (overnight).
8. After reaction is complete place again on the Buchner funnel and wash with 100 mL 0.5
M Na2CO3 and 100 mL distilled water. Wash with 100 mL column storage buffer (1X
PBS containing 0.02% sodium azide and 14mM βME).
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9. Obtain four Econo-Columns, 1.5×50 cm. First add 5-7 cm of quartz sand and then add 15
cm of lactosyl Sepharose into each column. Allow the gel to settle while tapping the sides
of the column to remove internal air bubbles from the column.
10. Obtain the bacterial supernatant from the -20 °C freezer and begin to thaw on ice.
11. Wash the lactosyl Sepharose column with 10 column volumes of wash buffer (1X PBS
containing 14mM βME), approximately 80 mL (See Note 11).
12. Move the column(s) to a 4 °C fridge and gently add the sample lysate to the column,
allowing it to pass through using gravity (See Note 12).
13. Add 10 column volumes of wash buffer to remove unwanted protein and cell
contaminants from the column.
14. Remove the column from the 4 °C fridge and add approximately 3 column volumes of
elution buffer (1X PBS containing 14mM βME and 100mM lactose) to the column and
begin collecting 1.0-1.5 mL fractions in 1.5 mL microcentrifuge tubes.
15. Set the absorbance to 280 nm on the spectrophotometer. Using 1 cm quartz cuvette, blank
the spectrophotometer using wash buffer. Record each OD at 280nm for each sample
(See Note 13).
16. Calculate the protein concentration using the formula: OD280 × path length × extinction
coefficient (See Note 14). Fractions can be stored at -80 °C.
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17. To isolate functional Gal-1, prepare a PD-10 column by washing the column with 10
column volumes of PBS (See Note 15).
18. Carefully place 2 mL of protein containing fractions over the PD-10. Let the mixture
flow onto the gel and then elute with PBS.
19. Capture 1.0-1.5 mL fractions and measure the OD280. Determine concentration using
methods in step 16.
20. Store PD-10 column fraction in 4 °C for no more than six months.

3.3.3

H2K A/J-/- (A/J-/-) and A/J+/+ (WT) cell culture.

H2K A/J cells were cultured as described in Morgan.et al 161 and Jat et al 162.
1. Prepare the growth media: 500 mL of DMEM (High Glucose, L-Glutamine, Phenol Red,
and Sodium Pyruvate), 1% Penicillin/Streptomycin, 20% Hi-FBS, 2% Chick Embryo
Extract, and Interferon gamma (1X) (See Note 16).
2. Warm the media at 37 °C. Take a frozen cell vial from the liquid nitrogen storage. Thaw
frozen vial in the water bath (37 °C) until just a small ice pellet is visible (~2min). Under
sterile conditions (hood), pour the cells into a 15mL conical tube containing 9 mL of
warmed growth media and centrifuge for at 1200 rpm for 5-7min. Remove the
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supernatant without disturbing the cell pellet. Re-suspend the cell pellet by adding 2-4
mL of growth media and count the cells (See Note 17).
3.

Prepare a 175cm2 flask containing 20-30 mL of the warmed growth media and 40-60 µL
of the interferon gamma stock (at 10 µg/mL). Seed at a density of 5,555 cells/cm2. Place
the flask containing the cells into the incubator set at 33 °C and 10% CO2.

4. Change the cell growth media every day.
5. Split the cells at 60% to 70% confluency. Remove the growth media and wash the cells
twice with 5 mL of warmed PBS. Add 5 mL of warmed Trypsin/EDTA and incubate for
~5min in the incubator at 33 °C. Add 3 mL pre-warmed plain DMEM per 1 mL of
Trypsin/EDTA to inactivate the Trypsin/EDTA.
6. Place the content in a 50 mL conical tube and centrifuge at 1200 RPM for 5-7 min.
Remove the media without disturbing the cell-pellet.
7. Resuspend the cell pellet by adding 2-4 mL of growth media, count the cells, and plate
onto sterile 35mm glass-bottomed dishes at a density of 5,555 cells/cm2 (total volume 2
mL/plate). Incubate at 33 °C in 10% CO2.
8. Differentiate the confluent myoblasts when they reach ~80% confluency (See Note 18).
9. To differentiate, wash the confluent myoblasts twice with warmed PBS.
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10. Add differentiation media (2 mL/plate) with the respective treatment (0.11 µM Gal-1,
diluted in PBS) and incubate at 37 °C and 5% CO2.
11. Change the differentiation media and treatments every other day. After 2-4 days in
differentiation media and treatment, myotubes are ready for laser injury.

3.3.4

Laser Injury Assay and Quantification.

1. Culture A/J WT and A/J-/- cells as described in the cell culture section and prepare for
laser injury.
2. Obtain fully differentiated myotubes in 35mm glass bottom dishes.
3. Prepare the FM1-43 or FM4-64 dye stock solution (200 µg/µL): add 500 µL of cold
ultrapure water to a one vial (100 µg) of the dye (See Note 19).
4. Prepare the TCS SP2 two-photon confocal scanning microscope for the live cell imaging
experiment: The live cell chamber should have a temperature of 37 °C and 5% ambient
CO2.
5. Carefully wash one myotube dish with 1 mL of warm 1X PBS. Add 25 µL of FM1-43 or
FM4-64 dye to dish (for 2.5 µM final concentration of dye) and incubate at room
temperature for 5 min. Place 35mm dish into confocal incubation chamber. Open the
Leica LASX Imaging Software and select the FRAP application.
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6. Select the following settings modified from Carmeille et. al 166: Dimensions: 512×512;
pinhole: <0.8; zoom: 1; lens selection: 63X/1.40 oil; argon laser: 25%; 488nm (FM1-43)
or 647nm (FM4-64) laser power: on; intensity: 1.0; PMT: on; Live image: On and focus
on myotube or myofiber and stop; Gain: 400-800. Bleach Settings: Visible light: off;
405nm UV laser:100%; Select ROI:0.01 by placing cursor on the membrane; Bleach
Duration: myotubes (15s), myofibers (3s). Time course settings: Pre-bleach image:1;
Bleach:15s or 3s; post-bleach image: 30; Image intervals: 3-5s; Select Run Experiment.
7. Select up to five different myotubes to be injured in each dish.
8. Export images as .TIFF. Open ImageJ and create the following macro:
run("Set Scale...", "distance=137 known=50 pixel=1 unit=um
global");
n = 31
for(i = 1; i <= n; i++) {
run("Measure")
if (i < n) {
run("Open Next")
}
}
9. Open pre-image and under “analyze” tab select set scale…; Distance in pixels: 137;
known distance: 50 µm; check global. Select plugin open Laser injury macro and select
“run” (See Note 20). Use free hand tool to outline region of interest (ROI abbreviation
used in ImageJ software) around total injured area and select “run”. Copy “label”, “area”,
and “mean gray value” from output table and calculate the fluorescence change (Δmean
grey value×area) in Microsoft Excel.
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10. Analyze fluorescence change differences between treatment groups using a multiple
comparisons test in preferred statistical program (Fig. 2).

3.3.4.1 Activity of Carbohydrate Recognition Domain in Membrane Repair.
1. Follow the method for laser injury and quantification but replace wash in step 3 with
PBS enriched with 20mM lactose (to bind CRD), or 20mM sucrose (as a control) and
incubate the myotubes for 10 min before injuring (Fig 3.3).

3.3.4.2 Examination of Galetin-1 Calcium Dependency in Membrane Repair
1.

Refer to the laser injury section and replace step 3 with the following: Wash the
myotubes with PBS and incubate the treatment groups in PBS enriched with: 1 mM
Ca2+ (as CaCl2), 1 µM intracellular BAPTA-AM in DMSO as a vehicle, or 1 µM
EGTA, for 10min.

2.

Resuspend Fluo-4 AM by adding DMSO to a final working concentration of 1-5 µM
and incubate with myotubes for 15-60min at 37 °C before laser injury. Incubate with
FM4-64 for 5 min prior to injury.

3.

Quantify Fluo-4 fluorescence change using the ImageJ methods mentioned above
(Fig 3.3 & Fig 3.4).
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A

B

C

D

F

E

Figure 3.3. Laser Injury Assay in Myotubes and Myofibers Under Varying Conditions.
A Representative image of A/J-/- myotubes or B myofibers during laser injury assay at
specific time-points (0 s represents end of injury; -25 s represents 25 s before the end of
injury). Quantification of change in fluorescence inside A/J myotubes C, E and
myofibers D, F after injury. Notice that these specific assays measure the change in
internal fluorescence among varying treatment groups. This research was originally
published in PLoS ONE (Reference 42).
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B

A

D

C

Figure 3.4. Galectin-1 Influences Membrane Repair Independent of Calcium. A Laser injury quantification
of myotubes supplemented with or without Ca2+. B Laser injury experiment using EGTA as an extracellular Ca2
+
chelator. C Laser injury experiment using BAPTA-AM as a cytosolic Ca2+ chelator. D. Representative images
showing the Ca2+ independence of Galectin-1. Notice the lack of Ca2+ recruitment at the injury site (indicated by
arrow) in A/J-/- myotubes. This research was originally published in PLoS ONE (Reference 42).
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A

B

Figure 3.5. Calcium-dependent repair in A/J WT myotubes. A Representative images of
A/J WT myotubes. Fluor-4 AM fluorescence at site of injury (shown by arrow) indicates
Ca2+ accumulation. B) Quantification of the change in Fluor-4 AM fluorescence over time
at the site of injury. Error bars indicate SEM. This research was originally published in
PLoS ONE (Reference 42).
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3.3.5

Labeling Galectin-1 Amines and Confocal Visualization

3.3.5.1 Labeling Galectin-1 Amines
1. Conjugate purified Gal-1 with Alexa Fluor 647 or fluorophore of choice using the
protocol provided with the protein labeling kit (Molecular Probes) with a few
alterations as described in Stowell et.al 160.
2. Alterations in labeling Alexa Fluor 647 Gal-1:
a. Desalt Gal-1 (3-5 mg/mL) through the PD-10 column that has been equilibrated
with PBS.
b. Take a 400 µL aliquot of Gal-1 and mix it with 50 µL of 1M lactose solution and
50 µL of 1M NaHCO3 solution (final concentrations 100 mM lactose and 100 mM
NaHCO3) (See Note 21).
c. Mix this solution with Alexa Fluor 647 at pH 7.4 and incubate on a stir plate for 90
min.
d. After the 90 min, pass through a Sephadex G25 column that was previously
equilibrated with 0.2 mM NaN3 in PBS.
e. Test activity of the carbohydrate recognition domain by running the labeled
Gal-1 on a lactose-Sepharose column. Any Gal-1 that does not adhere to the column
did not retain its carbohydrate recognition domain activity. Determine the
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concentration of Gal-1 and Alexa Fluor 647 labeled Gal-1 with absorbance at 280nm
or a Pierce™ Coomassie (Bradford) Protein Assay Kit (ThermoScientific).
3. Treat confluent myoblasts or differentiated myotubes with Alexa Fluor 647 labeled
Gal-1 Use for laser injury assay with the following settings: apply FRAP settings as
described above and turn 633 nm laser on power 1. (Fig. 3.6).

3.3.5.2. In Vitro Confocal Immunofluorescence Using Alexa Fluor 647 labeled Gal-1
1. Seed 5,555 A/J-/- cells/cm2 on a 35 mm glass culture dish. Grow myoblasts to 80%
confluent and differentiate and treat with 0.11 µM Alexa Fluor 647 labeled Gal-1. All
steps including Alexa Fluor 647 labeled Gal-1 treatment should be protected from light.
2. In a separate vial add 5 µL CellBriteTM Green Cytoplasmic Membrane Dye per 1 mL
of differentiation media. Prior to fixation, remove the differentiation media and add 300
µL of CellBriteTM solution to each plate and incubate for 20mins at 37 °C.
3. Remove CellBriteTM staining media and wash two times with 500 μL of warm PBS.
4. Fix cells by adding just enough warm 4% PFA to cover the cells (300-500 μL) for 10
min at 37 °C at various time points during differentiation (10 min, 4h, 8h, 12h, 24h, and
48h).
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5. Aspirate the 4% PFA and wash by adding 500 µL of PBS and rock at room
temperature for 5 minutes. Repeat wash two more times.
6. Add 300 µL of Hoecht staining solution (0.1 µg/mL) and incubate 10min at room
temperature. Wash with 300-500 µL of confocal wash buffer for 5min at room
temperature, racking. Repeat wash two more times.
7.Mount cells by adding a small drop (~10 µL) of ProLongTM Diamond Antifade
mountant and carefully cover using an 18 mm circle glass coverslip. Let the mountant
dry overnight and seal the coverslip sides with clear nail polish to secure the coverslip
in place.
8. Image on the confocal microscope using the appropriate settings: Open Leica Imaging
software and select TCS SP8 application; Speed: >600; Frame Average: 3.00; Pin hole:
0.3; Z Stack: 0.1-0.5 µm each plate; Turn laser on; Argon: 25%, [Set Sequence 1: 405
nm UV laser: on; Power: 1.0%; Visible Light: on, 633 nm laser power: 1.0; HyD 1:
Hoechst, HyD 3: Alexa Fluor 647 labeled Gal-1]. [Set sequence 2: Visible Light: on,
488 laser power: 1.0; HyD 2: CellBriteTm Green]; Zoom: 1.0; Search Dimension: 512 ×
512; Zoom: 4.0; Image Dimension: 2048 × 2048 (Fig. 6).
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B
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3.3.6

Muscle Fiber Isolation

1. Prepare a 12-well digestion plate in the following manner: For each extracted muscle,
fill 2 wells with 1 mL of plain DMEM and 1 well with 1 mL of PBS. (This leads to a

Figure 3.6. In vitro Galectin-1 Localization Using Confocal Microscopy. Representative images visualizing
Galectin-1 after 10 min in A and 48h in B myotube treatment and subsequent laser injury. Notice accumulation
total
of three atwells
digested
muscle.)
of Galectin-1
fluorescence
site ofper
injury.
The white
box indicates the area that is zoomed in on in the images,
and the white arrow indicates the injury site. Zooms are approximately 2.75x larger than the original. C.
Immunofluorescence experiment showing Galectin-1 lattice formation at 8h post-treatment in A/J-/- myotubes.
2. isPrepare
µLforming
of digestion
for each
muscle.
The gal-1
shown in100
green,
a lattice solution
between fusing
myotubes.
Blue indicates the nuclei and red
indicates the cellular membrane. The x-z and y-z slices are also shown, indicating that the Gal-1 is uptaken by
the myotubes at some point between treatment and the time point indicated. This research was originally
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3. After preparation of digestion plate, euthanize mice in accordance with approved
protocols.
4. After euthanization, extract desired muscle groups (See Note 22 and Note 23).
a. Flexor Digitorum Brevis: use pins to place hindfoot in complete
dorsiflexion. Make small incision at heel and remove skin from bottom of
footpad. Cut the proximal flexor digitorum brevis (FDB) tendon as close
to the heel as possible and lift FDB body up and away from the foot. Cut
all tendon from digits.
b. Tibialis Anterior: Place mouse supine and remove skin from lower leg.
Slide forceps under tibialis and separate tibial attachments. Cut at
proximal and distal tendons.
5. After extraction, place the muscle into a well with DMEM.
6. After all muscle groups are extracted, add an additional 100 µL of digestion solution
to each well containing a muscle.
7. Digest muscles for 60-120 minutes at 37°C (See Note 24).
8. Transfer muscles to a well with plain DMEM and allow to sit at for 10-15 minutes at
37°C.
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9. Transfer muscles to a well with PBS to allow for better visualization of the individual
fibers. Under a dissection microscope, locate properly digested myofibers and use a
small-bore pipette to transfer to a 35mm Glass Bottom Microwell Dish. After
transferring the desired number of myofibers, bring the final volume of the dish to
300 µL with warm PBS.
10. Allow the myofibers to attach to 35mm dish for 10-15 minutes.
11. Add 15 uL of FM1-43 and allow to incubate for 5-7 minutes before beginning injury.
12. Select at least three different myofibers in each dish to be injured as described in
section 3.4. Viable muscle fibers will have intact membranes and visible striations
(See Note 25).
13. Measure the total change in fluorescence intensity of FM™ 1-43 dye at the site of the
wound for each time point relative to the pre-injury fluorescent intensity using ImageJ
(Fig. 3) 163.

3.4

Notes
1. Avoid thermocycling the restriction digest enzyme to keep at optimum level of activity.
Keep on ice or at -20 °C, per manufacturer’s instructions.
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2. Make sure to set the right temperature and time during the entire digestion process to
maximize the effectiveness of expression of the gene of interest (GOI).
3. The total volume of the assembly reaction must be 20 µL.
4. See the full transformation protocol for BL21(DE3) at
https://www.neb.com/protocols/0001/01/01/transformation-protocol-for-bl21-de3competent-cells-c2527.
5. DNA purification was performed with E.Z.N.A Plasmid DNA Mini Kit I Protocol.
6. Sequence was confirmed by ETON Bioscience (San Diego, CA).
7. Preparation of LB broth: For each L of media, use 20g of LB broth powder. To sterilize
the mixture, autoclave on a 20 min cycle and then allow it to cool to room temperature.
8. You can stop here. If so, keep the bacterial pellet at -80 °C (up to 2 weeks).
9. Measure the pH with a pH indicator strip. The mixture is solid and can damage a pH
meter probe.
10. Divinylsulfone is very toxic and all steps including it should be conducted in a fume
hood. Avoid skin contact. Sepharose mixture will turn slightly pink.
11. For best results use gravity washing. To reduce washing time, you can pressurize the
column with compressed air.
12. To increase protein yield, pass the first flow through the column again after the elution
step. The sepharose can become saturated during the first flow through.
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13. Be sure to use a quartz cuvette, plastic absorbs at 280 nm which will cause false positive
OD readings.
14. Protein concentrations can be determined using Bradford assay (detection sensitivity
limit around 2 mg/mL) or Beer’s Law. Do not conduct a BCA assay to determine protein
concentration. BCA assay is a very common protein assay which reduces Cu2+ to Cu1+,
resulting in color change. The elution buffer contains two reducing reagents, 0.1% βmercaptoethanol (βME) and 100 mM lactose, which will create an artificial signal and
falsely increase the protein concentration. Know the specific concentration at which
your galectin will precipitate out of solution and dilute in PBS as necessary.
15. PD-10 is a desalting column which will remove lactose and βME.
16. Important: Interferon gamma (500X) needs to be added at the moment of plating. Add 2
µL of Interferon gamma /mL of growth media.
17. Re-suspended cells were counted by using the TC20 Automated Cell Counter (Bio-Rad)
and Courting Slides, Dual Chambers for Cell Counter (Bio-Rad).
18. We have observed myoblasts overcrowding when differentiating >90% in 35mm glass
bottomed plates. This inhibited the formation of mature myotubes.
19. The FM1-43 dye is light sensitive. Prepare and store the dye on ice and under dark
conditions.
20. This is to locate the injury site to accurately draw ROI around total fluorescence change.
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21. Lactose was used to prevent binding of Alexa Fluor 647 to the carbohydrate recognition
domain in order to maintain its functional activity.
22. It is possible to digest larger muscle groups, such as the gastrocnemius or quadriceps,
but the user must be careful not to over digest. This can be mitigated by lower
concentrations of collagenase 2 in the digestion solution. We have found more even
digestion using smaller, thinner muscle groups.
23. When removing muscle groups, take care not to stretch the muscle. This can result in
broken myofibers.
24. When properly digested, the muscle bundles will have a frayed or mop-like appearance.
25. Avoid injuring fibers with bends and kinks. Do not injure near nuclei. FM1-43 will stay
viable for up to 20 minutes.
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CHAPTER 4: THERAPEUTIC BENEFIT OF GALECTIN-1: BEYOND MEMBRANE
REPAIR, A MULTIFACETED APPROACH TO LGMD2B

Vallecillo-Zúniga, M.L., Poulson, P.D., Luddington, Jacob S., Arnold, Christian J., Rathgeber,
Matthew F., Kartchner, Braden C., Hayes, Spencer., Gill, Hailie N., Valdoz, Jonard C., Spallino,
Jonathan L., Garfield, Seth, Dodson, Ethan, Arthur, Connie M., Stowell. Sean R., and Van Ry,
Pam M.
Cells 2021, 10(11), 3210; https://doi.org/10.3390/cells10113210

Abstract
Two of the main pathologies characterizing dysferlinopathies are disrupted muscle
membrane repair and chronic inflammation, which lead to symptoms of muscle weakness and
wasting. Here, we used recombinant human Galectin-1 (rHsGal-1) as a therapeutic for LGMD2B
mouse and human models. Various redox and multimerization states of Gal-1 show that rHsGal1 is the most effective form in both increasing muscle repair and decreasing inflammation, due to
its monomer-dimer equilibrium. Dose response testing shows an effective 25-fold safety profile
between 0.54-13.5 mg/kg rHsGal-1 in Bla/J mice. Mice treated weekly with rHsGal-1 showed
downregulation of canonical NF-κB inflammation markers, decreased muscle fat deposition,
upregulated an-ti-inflammatory cytokines, increased membrane repair, and increased functional
movement compared to non-treated mice. Gal-1 treatment also resulted in a positive self96

upregulation loop of increased endogenous Gal-1 expression independent of NF-κB activation.
Similar reduction in disease pathologies in patient-derived human cells demonstrates the
therapeutic potential of Gal-1 in LGMD2B patients.
Keywords: Galectin-1; LGMD2B; membrane repair, NF-ƘB; inflammation; cytokines;
muscular dystrophy.

4.1 Introduction
Dysferlin is a 230-kDa protein that is highly expressed in skeletal muscle and involved in
membrane repair 148. Membrane repair is essential for maintaining cell integrity and is crucial for
stressed skeletal muscle fibers. 41, 192, 193 Mutated dysferlin leads to compromised membrane
integrity and repair, resulting in the phenotypes associated with Miyoshi Myopathy (MM) and
Limb-Girdle Muscular Dystrophy 2B (LGMD2B). In addition to diminished membrane repair,
muscles in LGMD2B are characterized by wasting, fatty infiltrate (especially in the hip and
lower leg), and chronic inflammation. 34, 184, 185, 194, 195
Chronic inflammation is responsible for many pathologies seen in LGMD2B. 149, 181, 196 In
particular, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling
complex is highly upregulated in this disease. 197 The NF-κB signal can work through either the
canonical or non-canonical pathway. Studies show that Galectin-1 activates the canonical NFκB pathway in osteoarthritis chondrocytes.198 The non-canonical NF-κB pathway is associated
with the production of proinflammatory cytokines in cardiac tissues and development of tumor
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necrosis. 199, 200 In this study we show that Gal-1 reduces expression of the NF-κB proteins in
LGMD2B models. Inflammation leads to diminished muscle regeneration, increased production
of proinflammatory cytokines, and aberrant phagocytic response. 149, 201, 202 These factors
contribute to the muscle wasting, fibrosis, and fatty deposition seen in dysferlinopathies.
Presently, there is neither a cure nor targeted treatment for LGMD2B. Therapies for this
disease focus on maintaining muscle strength and ambulation in patients and controlling chronic
inflammation. 77, 203 Although glucocorticoids have been used as anti-inflammatory treatments in
other muscular dystrophies, many do not have the same effect in LGMD2B. For example, certain
glucocorticoids, such as deflazacort, have detrimental effects on muscle strength and
inflammation in LGMD2B. 179 However, there are some steroid treatments showing promise as a
therapeutic in animal models of the disease. 109 More viable therapies for LGMD2B, such as
protein treatments, are needed.
Gal-1 is a β-galactoside-binding protein that exists in a dynamic equilibrium between
monomer and dimer states. 81 This equilibrium, along with the activity of its carbohydrate
recognition domain (CRD), contributes to the multifunctional properties of this protein. 204-206
Due to a relatively high density of cysteine residues on the surface of the protein, Gal-1 is
particularly sensitive to changes in the redox environment. 93, 207 The CRD is active when Gal-1
is reduced and inactive when Gal-1 is oxidized. 206 Previous studies show both mouse and human
Gal-1 reduced disease pathology in the mdx mouse model of Duchenne muscular dystrophy. 95
There were no reports of adverse immunogenicity while using human Gal-1 in the mouse model.
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Additionally, we did not observe adverse reactions or signs of elevated inflammation in our
previous or current study. 42 This is likely because human and mouse Gal-1 sequences are 88%
homologous. Although there are some minor structural differences, the CRD residues are 100%
conserved between species (https://blast.ncbi.nlm.nih.gov/Blast.cgi). For these reasons, we used
the human form of Gal-1 in our in vitro, ex vivo, and in vivo studies. In this paper, we
demonstrate that the reduced dimeric form of Gal-1 is responsible for inducing improvements to
muscle membrane repair, while the monomeric form is responsible for changes in inflammation.
Here, we not only present in vitro and in vivo results in mice, but also present significant data in
patient-derived dysferlin-deficient human myotubes, substantiating our claim that Gal-1
treatment increases muscle repair and decreases markers of inflammation. Previous research
shows that both of these processes lead to increased functional activity in dysferlinopathy
models.

4.2

Materials and Methods

4.2.1

Galectin-1 construction, production, and purification
Recombinant Human Galectin-1 (rHsGal-1) was produced and purified as described in

Vallecillo-Zúniga et. al.42 In summary, LGALS1 gblock was cloned into the pET29b(+) vector
and transformed into BL21(DE3) competent E. coli cells, grown, and induced with 0.1mM
IPTG. rHsGal-1purification was accomplished as described in Stowell et. al.160 rHsGal-1
bacterial lysate was passed through a lactoyl-Sepharose column (Sigma-Aldrich, St. Louis, MO).
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Galectin was eluted with 14mM β-mercaptoethanol (βME) and 100mM Lactose in 1X PBS.
Protein fraction absorbance was read at 280 nm on BioPhotometer (Eppendorf, Hamburg,
Germany) and fractions with an absorbance of greater than 0.5 were kept and stored in -80 ̊C. To
activate the CRD, factions were passed over a PD-10 desalting column (GE Health Care,
Chicago, IL) and stored at 4 ̊C.
Monomeric Galectin-1 (mGal-1) was constructed, produced, and generously provided by
Dr. Stowell at Emory University. This was achieved by capping the N-terminus with Lys, which
severely inhibits Gal-1 dimerization.87 Dimeric Galectin-1 (dGal-1) was constructed using a 2
Gly residue linking the N-terminus of one subunit to the C- of the other. The rHsGal-1GG
construct which contains two rHsGal-1 CRDs was connected by a glycine–glycine linker that
maintains the CRD orientation of wild-type galectin-1. The nucleotide sequences were
constructed in SnapGene (GSL Biotech, Chicago, IL) Vector assembly was completed by Twist
Bioscience (San Francisco, Ca). dGal-1 purification was accomplished as described in Stowell et
al.160 mGal-1 and dGal-1 forms were either left in a native reduced form or oxidized using 1μM
H2O2.206

4.2.2

Animals
Three- to nine-month-old male Bla/J mice (Dysf-/- (B6.129-Dysftm1Kcam/J) were provided

by the Jain Foundation. Mice were housed in an approved facility at Brigham Young University.
All procedures were performed in accordance with Brigham Young University IACUC-approved
100

protocol. Purified rHsGal-1 was used as a treatment in in vivo studies. Protein concentration was
analyzed using a Bradford assay protocol following the manufacturer’s instructions. BLA/J mice
were weighed and dosed with various doses of rHsGal-1. Treatment was delivered with 1 mL
insulin syringes (BD, San Jose, CA Cat #329420) intraperitoneally (IP).

4.2.3

Cell Culture
Immortalized primary H2K A/J-/- (A/J-/-) myoblasts were cultured as described

in Vallecillo-Zúniga et. al.42 Mouse myoblasts were plated onto T75 flasks (SARSTED No.
83.3911.302, Newton, NC) or standard 35 mm glass bottom dishes (Mat Tek, No. 1.5 Coverslip,
14 mm Glass Diameter, Uncoated. Ashland, MA), seeding at a density of 5,555 cells/cm2 and
incubated at 33°C in 10% CO2. At 80-90% confluency, myoblasts were differentiated and treated
with or without 0.1 µM rHsGal-1 for 48-72h at 37°C and 5% CO2. Twitching of myotubes was
quantified using ImageJ by selecting 10 different fields of view and calculating the number of
visible twitching myotubes over the total number of myotubes present.
Patient-derived dysferlin deficient cells (cell line “814”) were given courtesy of the Jain
Foundation, Dr. Simone Spuler, and Dr. Vincent Mouly. The dysferlin mutation was in Exon 38:
c.4022>TC HMZ, r.4022U>C, p. L1341P (Homozygous). The tissue originated from the vastus
lateralis from a 60-year-old of unknown gender. Human myoblasts were cultured in Promo Cell
skeletal muscle growth and differentiation medium (Cat. No.C-23060 and C-23061, PromoCell
GmbH, Germany).
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4.2.4

Muscle Fiber Isolation
Muscle fiber isolation was performed as described in Vallecillo- Zúniga et.
al.42 In summary, a 6-well plate (Cat. No. 665 180, Grenier Bio-One) was used as digestion
plate and prepared as described in Demonbreun et. Al. 208 When the mice were sacrificed,
the flexor digitorum brevis (FDB) was excised. Non-muscle tissue including tendon, nerve,
and overlying fascia were carefully removed, and muscles were incubated in Collagenase II
(2.5 U/ml, ThermoFisher, #17101015) in DMEM for 60-90 min at 37 °C. Next, by using a
small-bore pipette, the fibers were transferred to 35 mm Glass Bottom Microwell Dishes
(Cat. No. P35GCol-1.0-14-C, MatTek, Ashland, MA) and allowed to attach for at least 15
min.

4.2.5

rHsGal-1 in vivo treatment
Purified rHsGal-1 concentration was analyzed using a Bradford assay protocol as

described by Fanglia He.209 To keep rHsGal-1 solutions sterile, all dilutions were done inside a
biosafety cabinet. BLAJ mice were weighed and dosed with 2.7 mg rHsGal-1 per kilogram of
mouse. Mice were restrained using the scruffing technique detailed in Macholz et. al.210 and the
treatment was delivered with intraperitoneal injection, midway between the medial and sagittal
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line in the abdomen of the mouse. Mice were injected using BD 1mL Insulin Syringes with BD
Micro-Fine IV Needles (0.35mm x 12.7 mm).

4.2.6

Laser Injury
Laser injury assay was performed as described in Vallecillo et. al.42 A/J-/- non-treated or

treated myotubes were prepared for laser injury in 35 mm Glass Bottom Microwell Dishes (Cat.
No. P35GCol-1.0-14-C, MatTek, Ashland, MA). After washing with PBS, the myotubes were
incubated for 10 min in PBS enriched with 2.5 μM FM™ 1–43 dye (N-(3Triethylammoniumpropyl)-4-(4-(Dibutylamino) Styryl) Pyridinium Dibromide)3,5
(ThermoScientific, Cat. No. T35356, Waltham, MA) for 5 min before injury. Digested rHsGal-1
or PBS treated Bla/J myofibers were placed onto a 35 mm Glass Bottom Microwell Dishes (Cat.
No. P35GCol-1.0-14-C, MatTek) containing 300 µl of PBS. Myofibers were incubated with 2.5
μM FM™ 1–43 dye (N-(3-Triethylammoniumpropyl)-4-(4-(Dibutylamino) Styryl) Pyridinium
Dibromide)3,5 (ThermoScientific, Cat. No. T35356, Waltham, MA) for 5 min before injury. The
kinetics of repair was examined by determining the total change in fluorescence intensity of
FM™ 1–43 dye (ΔF/F0, where F0 is the original value at time 0) at the site of the wound for
each time point relative to the pre-injury fluorescent intensity that was measured using ImageJ.163

4.2.7

RayBio Mouse Inflammation Array
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Media from NT and rHsGal-1 treated A/J-/- myotubes were collected after 48h. Cytokine
expression was measure using the Mouse Inflammatory Array C1 (RayBiotech, Cat.No.AAMINF-1-8, Peachtree, GA) according to manufacturer’s instructions. Membranes were imaged
using FluorChem imaging system (Alpha Innotech, San Jose, CA) The membranes were
quantified using ImageJ software as described in Schindelin et al. 211

4.2.8

Immunofluorescence
A/J-/- myoblasts were cultured onto 35 mm Glass Bottom Microwell Dishes (Cat. No.

P35GCol-1.0-14-C, MatTek, Ashland, MA), were fixed in 4% paraformaldehyde, permeabilized
in 0.1% triton X-100 (in PBS) and blocked using PBST blocking solution for 1h at room
temperature. The myotubes were then incubated overnight at 4°C with the appropriate primary
antibody: NF-κB p65 (Cat. No. 8242s, Cell Signaling, 1:5000), Phalloidin-Alexa Fluor 647 (Cat
No. A2287, Invitrogen, 1:50), β-Tubulin Loading Control, BT7R, (Cat. No. MA5-16308,
ThermoScientific, 1: 2,000), GAPDH (Cat. No. MA5-15738, Invitrogen, Rockford, IL, 1:1000),
and Anti-β-actin (Cat. No. A5441, Sigma-Aldrich, St. Louis, MO. 1: 5,000). After washing
primary antibodies, blots were probed using the following secondary antibodies: Goat antiMouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Cat. No.
A32723, ThermoFisher, 10 μg/ml) or Alexa Fluor 555 goat anti-rabbit secondary antibody (Cat
No. G-21234, 1:1500; Invitrogen). Nuclei were counterstained with Hoeschst 33342 (Cat No.
62249, ThermoScientific, 1 μg/ml) or 4’,6-diamindino-2-phenylindole (DAPI) (Cat No. 62248,
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Thermo Scientific, 1:500). Myotubes were mounted on coverslips using ProLong™ Diamond
Antifade Mountant (Cat No. P36965, Invitrogen) and dried overnight. Images were taken on the
A TCS SP2 two-photon confocal scanning microscope with LASX imaging software (Leica
Microsystems Inc., Buffalo Grove, IL). Fixed Bla/J psoas muscle sections were washed with
PBS three times for 5 mins each. The sections were then permeabilized in 0.1% Triton X-100 for
15 min and subsequently blocked with EZ-Block PBST (VWR, CAT NO. 10005-262) for 1 h at
room temperature. Primary antibodies anti-Perilipin, (Cat.No.9349, Cell Signaling Technology,
1:100, and 6x-His Tag Monoclonal Antibody (HIS.H8), (Cat. No. 14-6657-80 Invitrogen,
1:1000, were diluted in the wash buffer (10% EZBlock in PBST). The slides were left with the
primary antibody overnight at 4°C. The following day the slides were washed three times with
the wash buffer for 5 min, after which the slides were blocked with 3% hydrogen peroxide in
methanol. The slides were then washed three times with PBS for 5 min each. The slides were
then treated with the HRP conjugated secondary antibody (1:500, Invitrogen, Cat. No. G-21234)
and left for 1 hour at room temperature. The slides were then rinsed once with PBST; after which
they were washed with PBST twice PBST for 5 min each. The slides were then washed with
PBS once for 5 min and then rinsed once with PBS. DAB (Thermo Scientific, 34002) was
prepared according to the manufacturer’s instructions. The slides were treated with DAB for 15
min and counterstained with hematoxylin for 4 minutes, washed with 100% ethanol, allowed to
air dry and then washed three times with Histo-Clear for 5 minutes each. Finally, the slides were
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mounted using Organo/Limonene mounting medium (Sigma-Aldrich, O8015) and cured
overnight at 37°C before imaging.

4.2.9

Western Blotting

Whole cell lysates from A/J-/- myotubes (at 2 to 4 days) and Bla/J gastrocnemius muscles were
prepared using RIPA lysis buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and 1 mM PMSF) and Halt™ Protease
and Phosphatase Inhibitor Single-Use Cocktail (100X) (Cat No. 78442, ThermoScientific).
Protein concentration was determined using the Pierce™ BCA Protein Assay Kit
(ThermoScientific). Proteins samples were separated under standard conditions on 6%-20%
SDS-PAGE gels and transferred onto Nitrocellulose Membranes 0.2 μm (Bio-Rad, Cat
No.1620150, Hercules, CA) through electro-blotting. After blocking with 5% w/v non-fat dry
milk in 1X TBST, membranes were probed overnight for the following mouse, rabbit, or goat
monoclonal and polyclonal antibodies: 6x-His Tag Monoclonal Antibody (HIS.H8), (Cat. No.
14-6657-80 Invitrogen, 1:1000), Galectin-1 Monoclonal Antibody (6C8.4–1) (Cat. No. 43–7400,
Invitrogen 1:1000), TAK-1 Polyclonal antibody (Cat. No. PA5-17507 Invitrogen, 1:1000), NIK
Polyclonal antibody (Cat. No. PA5-100732 Invitrogen, 1:1000), NF-kB p65 (Cat. No. 8242S
Cell Signaling, Boston, MA. 1:1000), Phospho-NF-kB p65 (Cat. No.3033S, Cell Signaling,
1:1000), IkBα (Cat. No.4814S, Cell Signaling, 1:1000), β-Tubulin Loading Control (Cat. No.
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2146S Cell Signaling, 1:1000), GAPDH (Cat. No. MA5-15738, Invitrogen, Rockford, IL,
1:1000), and Anti-β-actin (Cat. No. A5441, Sigma-Aldrich, St. Louis, MO. 1: 5,000). After
washing primary antibodies, blots were probed using the following secondary antibodies:
IRDye® 800CW Donkey Anti-Rabbit IgG (H + L) (Cat No. 926–3221, Licor, Lincoln, NE, 1:
15,000), Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor
Plus 800 (Cat No. A-32730, Invitrogen, 1: 40,000), Goat anti-Mouse IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor 680 (Cat. No. A-21058, Invitrogen, 1: 5,000), and
IRDye® 680RD Donkey Anti-Goat IgG (Cat. No. 926–68074, Licor, 1:5000). The blots were
developed using the Odyssey CLx (Model No. 9140, Li-Cor, Lincoln, NE). Quantifications were
done by using ImageJ as described in Schindelin et al.163

4.2.10 Histology
Bla/J psoas muscles were dissected, embedded in optimum cutting temperature
compound (OCT, Cat. No.4583, Sakura) and frozen isopentane cooled in a liquid nitrogen
bath.10μm of frozen tissues were cut using a TNF50 Semi-Automatic Cryostat (Tanner
Scientific). Sections were placed on a 3P white xtra slides (Cat. No. 3800200, Leica
Microsystems). Sections were processed for immunofluorescence. Digital images were captured
with an Olympus microscope (Model BX51).

4.2.11 Statistical Analysis
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Data analyses were completed by using Tukey’s multiple comparison test 1-way and 2way ANOVA, the Student’s t test through the GraphPad Prism Software version 9.0. For
membrane repair analysis, the data conferred are the averaged values for all the myotubes used in
the analysis, and the treatment at individual time points. P-values are indicated in the figure
when statistical significance is determined for all groups as described in the figure legends.

4.3 Results
4.3.1

Reduced dimeric Galectin-1 is responsible for optimal membrane repair
We designed several synthetic forms of Gal-1 to determine the effect of dimerization and

redox states on membrane repair in models of dysferlinopathy (Figure S4.1 & S4.2). These
forms include wild type Gal-1 (WTGal-1), transiently reduced recombinant Human Gal-1
(rHsGal-1), fixed monomeric Gal-1 (mGal-1), and fixed dimeric Gal-1 (dGal-1). WTGal-1 and
rHsGal-1 are structurally identical except for the addition of a 6X His-tag on the C-terminus of
rHsGal-1 and are comprised of the human LGALS1 gene. For mGal-1, an induced V5D mutation
prevents dimerization as shown by Cho et al. 87 We formed dGal-1 by fusing two human Gal-1
constructs with a flexible gly-gly linker, as described in Earl et. al. 212
Previous work from our lab showed that rHsGal-1 with a 6X his-tag diluted in PBS at a
pH of 7.4 beneficially increased membrane repair in dysferlin-deficient myotubes and explants.
However, we did not evaluate the effects such as the 6X His tag, alkylation, dimerization and
redox state. 42 Stowell et al. showed that alkylation of Gal-1 provides permanent protein stability
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through prevention of cystine residue oxidation, thus stabilizing the CRD of Gal-1.42, 213 β-ME is
a well-known temporary reducing agent that helps stabilize the protein of interest by cleaving the
disulfide bonds between cysteine residues. 214 As explained in the methods section, we purified
transiently reduced rHsGal-1 (under a β-ME environment) to ensure the protein stability. Prior to
experimental use of rHsGal-1, β-ME was removed by passing the protein through a PD-10
column. To test the activity of rHsGal-1 and WT Gal-1 in membrane repair, A/J-/- myotubes were
treated for 48 h with these two forms of Gal-1. After injury, no significant differences were
observed in fluorescent intensity between rHsGal-1 and WT Gal-1 treated myotubes (Figure
4.1A).
We next sought to compare the effects of permanently reduced rHsGal-1 (alkylated
rHsGal-1) and rHsGal-1 on membrane repair. After 48 h treatment, myotubes were subjected to
a laser injury. The change in fluorescent intensity was nearly identical between the alkylated
rHsGal-1 and rHsGal-1 (Figure 4.1B). Additionally, we found that the final fluorescence
intensity between rHsGal-1 and WTGal-1 was 54% and 40% lower when compared to nontreated myotubes, but not statistically significant between the two forms. These results indicate
no deleterious effects from the His-tag or alkylation.
The known interactions of Gal-1 are irrevocably connected to oxidation state. Thus,
identifying the relationship between membrane repair and oxidation state are vital to therapeutic
development. Previously, our lab showed that a 10 min treatment with rHsGal-1 markedly
improved membrane repair. 215 To test the relationship between oxidative state of mGal-1 and
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repair, we treated A/J-/- myotubes for 10 min with oxidized or reduced mGal-1, using rHsGal-1
as a positive control (Figure 4.1C). We saw no improvement in myotubes treated with reduced
mGal-1, but we observed an increased dye entry of 40% in myotubes treated
with oxidized mGal-1 compared to NT myotubes, indicative of decreased repair even when
compared to NT A/J-/- myotubes. We then treated A/J-/- myotubes for 48 h with either reduced
mGal-1, oxidized mGal-1, or rHsGal-1 (Figure 4.1D). After 48 h, we saw that both forms of
mGal-1 decreased dye entry by 41% compared to NT myotubes, while rHsGal-1 treated
myotubes decreased by 72%. The dichotomy of results from the 10 min versus the 48 h
treatments with mGal-1 suggest that a longer treatment is necessary for membrane repair when
using this form of Gal-1. This implies that signaling pathways must be activated in order for
either redox state of mGal-1 to have a therapeutic effect. This is consistent with reports that
monomeric Gal-1 is primarily involved in intracellular signaling. 91, 212, 216
To determine whether dGal-1 had similar limitations, we treated A/J-/- myotubes
with both oxidized and reduced dGal-1 for 48 h and performed the laser injury assay (Figure
1e). Compared to NT myotubes, oxidized dGal-1 treatment did not show any improvement in
membrane repair. However, reduced dGal-1 decreased dye entry by 82% which is slightly better
than the 66% decreased dye entry shown by rHsGal-1. Next, the reduced form of both mGal-1
and dGal-1 were tested on myofiber explants from Bla/J mice (Figures 1f and 1g). After a 2 h ex
vivo treatment with the various forms of Gal-1, we found that dGal-1 and rHsGal-1 decreased
final fluorescence by 40% and 57%, respectively (Figure 4.1F & 4.1G). Reduced mGal-1 did
110

not decrease fluorescence compared to PBS-treated myofibrils. These data suggest that the
dimeric form of Gal-1, as either fixed dGal-1 or rHsGal-1 in monomer-dimer equilibrium, is
required to improve membrane repair.
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Figure 4.1. HsGal-1 is the most efficient type of Gal-1 in helping improve sarcolemmal repair
in A/J myotubes and Bla/J myofibers. A. Quantification of the change in fluorescent intensity
inside A/J-/-myotubes following laser injury when treated with 0.11 μM WT Gal-1 and 0.11 μM
rHsGal-1 for 48 h compared to NT A/J-/- myotubes. * = NT vs 0.11 μM rHsGal-1. % = NT vs 0.11
μM WT Gal-1. B Change in the fluorescent intensity in A/J-/- myotubes following laser injury
when treated with 0.11 μM rHsGal-1 and 0.11 μM alkylated rHsGal-1 compared to NT A/J-/myotubes. C. Quantified laser injury assay displaying membrane repair differences between 10
min treatment of A/J-/- myotubes with 0.11 μM mGal-1 (oxidized), 0.11 μM mGal-1 (reduced), and
0.11 μM rHsGal-1 compared to NT. $ = mGal-1 (oxidized) vs. mGal-1 (reduced), % = mGal-1
(reduced) vs. rHsGal-1, # = mGal-1 (oxidized) vs. rHsGal-1, & = NT vs. mGal-1 (oxidized), * =
NT vs. rHsGal-1 D. Quantified laser injury assay displaying membrane repair differences
between 48 h treatment of A/J-/- myotubes with 0.11 μM mGal-1 (oxidized), 0.11 μM mGal-1
(reduced), and 0.11 μM rHsGal-1 compared to NT. # = mGal-1 (oxidized and reduced) vs.
rHsGal-1, & = NT vs. mGal-1 (oxidized and reduced), * = NT vs. rHsGal-1 E. Quantified laser
injury assay displaying membrane repair differences between 48 h treatment of A/J-/- myotubes
with 0.11 μM dGal-1 (oxidized), 0.11 μM dGal-1 (reduced), and 0.11µM rHsGal-1 compared to
NT. $ = dGal-1 (oxidized) vs. rHsGal-1, * = NT vs. rHsGal-1 and NT vs. dGal-1 (reduced) and
dGal-1 (oxidized) vs. dGal-1 (reduced) F. Quantified laser injury assay displaying membrane
repair differences between 2 h treatment of isolated Bla/J mouse myofibers with 0.11 μM mGal-1
(reduced), 0.11 μM dGal-1 (reduced), and 0.11 μM rHsGal-1 compared to PBS. $ = PBS vs.
dGal-1 (reduced), % = PBS vs. rHsGal-1, * = rHsGal-1 and dGal-1 (reduced) vs. mGal-1
(reduced) G. Representative images of treated explant Bla/J myofibers during laser injury assay
taken at 0 s, 3 s, 15 s, 30 s, 45 s, and 90 s with arrows indicating location of injury. All p-values
were calculated by Tukey's multiple comparison test and indicated by ****p< 0.0001,
***p<0.001, **p<0.01, and *p<0.05. Scale bars = 20 μm. Error bars represent SEM. n ≥ 23
from 2 independent experiments for each group.

4. 3.2 rHsGal-1 lowers expression of proteins in the NF-ΚB pathway
Chronic inflammation is a common disease pathology of LGMD2B and a desirable
therapeutic target. We hypothesized that Gal-1 would reduce certain NF-κB markers that are
upregulated in LGMD2B. We first examined the ability of our various recombinant forms of
Gal-1 to modulate activation of the NF-κB pathway. A/J-/- myotubes were treated for 48 h
with oxidized and reduced forms of Gal-1 and lysates were probed for p65. We found that only
rHsGal-1, oxidized mGal-1, and oxidized dGal-1 reduced p65 levels (Figure 4.2A &
4.2B). These results were confirmed via immunofluorescent imaging of p65 in A/J-/- myotubes
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(Figure 4.2C). Based on the fact that only rHsGal-1 produced optimal effect in both the injury
repair assay and NF-κB pathway activation, we used this form in the rest of our experiments.
There are two activation pathways of NF-κB inflammation: canonical activation via TAK1 and
non-canonical activation via NIK. It is unknown how Gal-1 activates the non-canonical NF-κB
pathway. As such, we wanted to determine which inflammatory pathway Gal-1 is regulated in
LGMD2B models. We achieved this by probing for the respective proteins of each pathway. The
rHsGal-1 treatment lowered levels of TAK1 by 84%, but did not induce changes in NIK,
indicating that the reduction in inflammation is due to modulation of the canonical NFκB pathway (Figures 4.2D & 4.2E). We further examined multiple proteins downstream of
TAK1, including IKBα, p50, and phospho-p65 (P-p65) (Figures 4.2F, 4.2G, 4.2H, & 4.2I).
These results show a dramatic decrease in inflammatory transcription factors p50 and P-p65, by
56% and 55%, respectively, as well as an increase in the inhibitory protein IKBα by 40%. This
overall reduction in inflammatory markers indicates that the monomeric rHsGal-1 is largely
responsible for the likely decrease NF-κB inflammation in cellular models of LGMD2B.
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Figure 4.2. In vitro treatment with rHsGal-1 modulates inflammatory response through the NF-κB pathway. A.
Quantification of expression levels of p65 (normalized to β-tubulin) in 48 h A/J-/- NT or 0.11 μM rHsGal-1 treated
myotubes. B. Western blot images showing the p65 expression in NT or 0.11 μM rHsGal-1 48 h A/J-/- treated
myotubes. C. Representative images of WT, and NT or 0.11 μM rHsGal-1 48 h A/J-/- treated myotubes cultured and
immunostained with p65 (green), Phalloidin (red), and DAPI (blue). D-H. Western blot quantification of 48 h NT or
0.11 μM rHsGal-1treated myotubes expressing levels of TAK1 D, NIK E, IKBα F, p50 G and P-p65 H, I. Western
blot images of 48 h NT or 0.11 μM rHsGal-1treated myotubes expressing NF-κB inflammatory subunits quantified
in D-H. n=3 in each group. A. *<0.05 and **<0.01 NT vs. all forms of Gal-1. D-H. *<0.05, **<0.01, ***<0.001
NT vs. rHsGal-1. Data are represented as SEM.
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4.3.3

The therapeutic window for un vivo rHsGal-1 is from 1.35 to 8.1 mg/kg
A broad therapeutic window is a desired trait for drug therapies. Based on our in vitro

dosage and the dosages used in the mdx DMD model, we predicted the therapeutic dosage for
our in vivo model to be 2.7 mg/kg 42, 95. Our previous work showed that an ex vivo treatment of
myofibers taken from SJL/J (Dysf-/-) and Bla/J mice 2 h prior to injury resulted in an increased
membrane repair capacity 42. Here we used ex vivo membrane repair assays to determine the
optimal rHsGal-1 dose and to define the in vivo therapeutic window in LGMD2B murine models
(Figures 4.3A, 4.3B; S4.2, S4.3 & Table 1). Intraperitoneal injections of Gal-1 have been
successfully utilized in other dystrophic mouse models 95. Wuebbles et al. showed that
intravenous (IV) rHsGal-1 doses greater than 2.5 mg/kg were lethal due to the ability of Gal-1 to
induce hemostasis and thrombosis 191. Thus, all doses were given intraperitoneally (IP). Day 7
(D7) doses were given 2 hours prior to sacrificing the mouse, based on previous work in the
Bla/J mouse model 42. The change in fluorescent intensity for each rHsGal-1 treatment was
normalized to PBS-treated myofibers to allow comparisons between experiments (Figures 4.3B,
S4.2, & S4.3). We found that most doses of rHsGal-1 either positively improved membrane
repair or had no detrimental effect. Only 27 mg/kg rHsGal-1 given IP three times a week proved
detrimental to membrane repair, although we observed no other signs of animal distress or
toxicity. Three doses, 1.35 mg/kg, 2.7 mg/kg, and 5.4 mg/kg, given at Day 0 and 7, proved to
have “clinically significant” impacts on membrane repair (greater than 2-fold change from PBStreated mice) (Figure 4.3B, inset).
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Since 9 out of the 12 dosing schemes included a day 7 treatment, we evaluated whether
the rHsGal-1 dose provided 2 hours prior to sacrifice was necessary to gain maximum
improvement in membrane repair. Mice were treated on either Day 0 only, Day 7 only, or Days 0
and 7. Laser injury assay showed that the combined Days 0 and 7 treatments improved
membrane repair the most (71% decrease in final fluorescence intensity). The individual Day 0
and Day 7 treatments also showed significant improvements to membrane repair (final
fluorescence intensity decreased 25% and 47%, respectively). This suggests that rHsGal-1
provides immediate and cumulative benefits to membrane repair (Figure 4.3C).
To assess the relationship of treatment schedule to the amount of rHsGal-1 in tissues, we
used a western blot analysis to probe for His-tag present in our rHsGal-1. We found that tissues
from mice treated on Days 0 and 7 had 87% more rHsGal-1 than mice treated on Day 0 and
220% more rHsGal-1 than mice treated on Day 7 (Figure 4.3D & 4.3E). Oxidized 3,3’Diaminobenzidine (H-DAB) staining showed that only tissues from Bla/J mice treated with
rHsGal-1 on Days 0 and 7 had significantly more rHsGal-1 in the tissues than non-treated mice
(Figure 4.3F & 4.3G). These results show that rHsGal-1 has benefits at both a 2 h and weeklong treatments and has additive effects on membrane repair with both treatments.
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Table 2. Membrane repair improvement factor based on the treatment dosage and schedule.
rHsGal-1 Dose

Treatment Schedule

Fold Improvement Over PBS

0.27 mg/kg

Day 0, 7

1.29 (ns)

0.27 mg/kg

Day 0, 2, 4, 6

1.64 (**)

0.54 mg/kg

Day 0, 7

1.08 (ns)

1.35 mg/kg

Day 0, 7

2.75 (****)

2.7 mg/kg

Day 0, 7

3.35 (****)

2.7 mg/kg

Day 0, 5

1.56 (***)

2.7 mg/kg

Day 0

1.52 (**)

2.7 mg/kg

Day 7

1.99 (***)

5.4 mg/kg

Day 0, 7

2.39 (****)

8.1 mg/kg

Day 0, 7

1.56 (*)

13.5 mg/kg

Day 0, 7

0.98 (ns)

Day 0, 3, 7

0.55 (**)

27 mg/kg
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Figure 4.3. 2.7 mg/kg rHsGal-1 is the best dose to improve membrane repair in vivo. A. Representative
image from laser injury assay on myofibers taken from Bla/J mice PBS or rHsGal-1treated in vivo. B.
Average end fluorescence change from several dosages and regiments of rHsGal-1. Points above red line
indicate increased membrane repair from control and points below indicate decreased membrane repair
from control. Inset shows representative graph of treatments with fold change >2. C. Laser injury
quantification of D0, D7; D0; and D7 treatments of rHsGal-1. *=D0,7 vs PBS; %=D7 vs PBS; #=D0 vs
PBS D. Quantification of His.H8 western blot. E. Western blot for His.H8 from gastrocnemius extracted
from mice treated PBS or rHsGal-1 for various treatment schedules. F. Representative images of H-DAB
staining for rHsGal-1 from specified treatment groups. G. Quantification of H-DAB intensity for rHsGal-1
in psoas. Values were measured by Tukey’s multiple comparison test and indicated by: ****p<0.0001,
***p<0.001, **p<0.01, and *p<0.05 between control and rHsGal-1 treated mice.
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4.3.4

One-month rHsGal-1 treatment improves translational and biochemical measures

of LGMD2B.
After determining that a 2x/week treatment of 2.7 mg/kg rHsGal-1 improved membrane
repair, we tested its efficacy during a one-month study. Nine-month-old Bla/J mice were treated
weekly with 2.7 mg/kg/wk rHsGal-1 for four weeks. At the end of the four-week study, we
assessed membrane repair capacity, functional activity, histopathology, and inflammation. Using
activity monitoring cages, we saw significant increases in rearing events (Z counts) and
horizontal movement (X counts) after the one-month treatment with rHsGal-1 (1.22 and 1.54fold difference, respectively; Figures 4.4B & 4.4C). Additionally, we found that membrane
repair was improved with a final fluorescence decrease of 51% compared to PBS treated Bla/J
mice (Figure 4.4A).
Studies in mdx mice and our previous study of A/J-/- myotubes showed that rHsGal-1
treatment resulted in a positive feedback loop resulting in upregulating endogenous Gal-1. 215 To
determine if this apparent positive feedback loop existed in vivo, we used RT-qPCR to determine
Gal-1 transcription levels in the psoas, the most affected muscle in the Bla/J mouse model. 217
We found a 7.5 and 18-fold increase in LGALS1 after 1-week (D0, D7 regiment) and 1-month
treatments, respectively (Figure 4.4D). This data provided evidence of a positive feedback loop,
where exogenous Gal-1 induces expression of endogenous Gal-1. An ELISA assay was used to
measure concentration of Gal-1 in serum. Results showed that there was a base line
concentration of Gal-1 of 6.9 ng/mL. A one-time IP treatment with 2.7 mg/kg revealed that the
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serum Gal-1 levels reach peak concentration at approximately 3 h and at 12 h had returned to
baseline concentration. The half-life of rHsGal-1 treatment in the blood of Bla/J mice is 2.9 h
(Figure 4.4I).
In order to determine if the reduction in inflammatory markers seen in vitro was recapitulated in
vivo, we probed for p65 in the psoas of mice treated with rHsGal-1 and PBS for one month.
Immunofluorescence imaging revealed a reduction in normalized area of p65 (Figures 4.4G &
4.4H). This was confirmed via western blot of the gastrocnemius muscle (Figures 4.4E & 4.4F).
Additionally, expression of other NF-κB proteins, p50 and phospho-p65, was significantly
reduced.
Patient and animal model histopathology shows upregulation of fibroadipogenic progenitors in
slow twitch myofibers which correlates to disease pathophysiology.218-220 To investigate the
effect of rHsGal-1 on this aspect of the disease, we probed psoas tissue sections for perilipin, a
marker of lipid infiltrate. We saw that the one-month treatment reduces perilipin area by 50%
(Figures 4.4J & 4.4K). Additionally, we observed that after 15 days, A/J-/- myotubes treated
with rHsGal-1 showed significantly more twitching ability compared to NT myotubes (Figure
S1, S4, & Supplemental Video 1). Together, these results show treatment with rHsGal-1
improves muscle function (activity), muscle membrane repair, pathology and inflammation.
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Figure 4.4. rHsGal-1 improves membrane repair and exploratory activity and decreases inflammatory markers
in Bla/J mice after one-month treatment. A. Quantification of laser injury on muscle from BLA/J mice treated for
one month with either 2.7 mg/kg rHsGal-1 or PBS. B. Average number of rearing events during first hour placed
in CLAMS cages for 2.7 mg/kg rHsGal-1 treated and PBS treated BLA/J mice. C. Average number of times the
mice crossed the x axis during first hour placed in CLAMS cages for 2.7 mg/kg rHsGal-1 treated and PBS treated
control BLA/J mice. (D). RT-qPCR results for Gal-1 gene expression in the psoas of Bla/J mice treated for 1 week
or 1 month with PBS (control) or 2.7 mg/kg rHsGal-1. E. Quantification of Western blot comparing levels of
Gal-1, His-Tag, p65, P-p65, p50, all normalized to β-tubulin control. Tissue was taken from Bla/J mice treated
with 2.7 mg/kg rHsGal-1 or PBS (control) for one month. F. Western blot images from homogenized muscle tissue
from PBS or 2.7 mg/kg rHsGal-1 treated BLA/J mice. G. Representative images of immunofluorescence done on
Bla/J mice treated for one month with 2.7 mg/kg rHsGal-1 or PBS (control). Samples were stained with p65,
DAPI, and Phalloidin.
(H). Quantification of immunofluorescence of p65 normalized to DAPI control on mouse psoas muscles either
treated with 2.7 mg/kg rHsGal-1 or PBS. I. Concentration of Gal-1 present in serum of Bla/J mice treated with
rHsGal-1 from time of treatment (t=0) to 72 hours after treatment. J. Quantification of perilipin stain in mouse
psoas muscles treated with PBS or 2.7 mg/kg rHsGal-1 for one month. K. Representative images of histology
performed on BLA/J mouse muscles treated with either PBS or rHsGal-1. Mouse psoas muscles were sectioned
and immunostained with perilipin (DAB) and counterstained with hematoxylin. Values for all graphs were
measured by Tukey’s multiple comparison test and indicated by: ****p< 0.0001, ***p<0.001, **p<0.01, and
*p<0.05 between control and rHsGal-1 treated mice.

4.3.5 rHsGal-1 treatment upregulates anti-inflammatory cytokine secretion in vitro and in
vivo
To further investigate the effect of rHsGal-1 treatment on the NF-κB pathway, we
quantified changes in secreted cytokines in dysferlin models with treatment. We tested cell
culture media of A/J-/- myotubes NT or treated with 0.11 μM rHsGal-1 using a mouse cytokine
profiler (Figures 4.5A & 4.5B). This assay revealed that IL-4, CXCL-1, MCP-1, and TIMP-2
cytokines were upregulated during 48 h rHsGal-1 treatment by 15.5, 1.4, 1.5, and 1.5-fold
respectively (Figure 4.5C). Although there are several functions for each cytokine, the
commonality between them is that each has either anti-inflammatory properties or promotes
tissue remodeling and regeneration (Figure 4.5D). For example, IL-4 is a multifunctional
cytokine critically involved in inflammation by promoting alternative macrophage activation. 197,
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221-224

Our results show that IL-4 is the foremost upregulated cytokine in myotubes after 48 h

rHsGal-1 treatment.
To confirm the cytokine secretome results, we tested cytokine expression in tissue lysates from
Bla/J mice treated with PBS or rHsGal-1 for one-month. We found a significant increase in IL-4,
MCP-1, and TIMP-2 in mice treated with rHsGal-1 compared to the PBS by 38.5, 1.9, and 1.4fold respectively (Figure 4.5E-4.5H). These results may explain the beneficial effect of rHsGal1 treatment in inflammation and membrane repair.

4.3.6

rHsGal-1 improves membrane repair in dysferlin deficient, patient-derived

myotubes.
With the goal to bring Gal-1 treatment to patients, we used dysferlin-deficient patientderived myotubes to verify that the therapeutic effects measured in mouse models would
translate to a human model. Patient myotubes treated with 0.11 μM rHsGal-1 experienced a 79%
reduction in final fluorescent intensity in laser injury assay, indicating increased repair (Figure
4.6A & 4.6B). Changes in inflammatory protein markers were investigated using
immunofluorescence and western blots. Quantification of p65 confocal immunofluorescent
images reveal a 47% reduction in p65 expression with the same trend using western blot analysis
(Figure 4.6C, 4.6D, 4.6E, & 4.6F).
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Figure 4.5. rHsGal-1 treatment upregulates anti-inflammatory cytokines. A. Cytokine array
expression from NT A/J-/- myotubes cultured in differentiation media for 48 h. B. Cytokine array
expression from A/J-/- myotubes after 48 h in differentiation media supplemented with 0.11 μM
rHsGal-1. C. Mean pixel density of relative cytokine expression from A and B. D. Schematic
reference of the significantly upregulated cytokines after 48 h treatment with 0.11 μM rHsGal-1.
E. Quantification of Western blot probing for IL-4. F. Quantification of Western blot of MCP-1
levels normalized to β-actin in cells treated with PBS (control) or 2.7 mg/kg rHsGal-1. G.
Quantification of Western blot of TIMP-2 normalized to GAPDH levels in cells treated with PBS
(control) or 2.7 mg/kg rHsGal-1. Tissues taken from mice treated for 1 month. H. Images of
Western blot for TIMP-2, MCP-1, β-actin, and GAPDH on tissues from Bla/J mice treated with
PBS (control) or 2.7 mg/kg rHsGal-1 for one month. n=4 for each group. *<0.05, **<0.01,
***<0.001, ****<0.0001 NT vs. rHsGal-1. Bars are represented as SEM.
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Figure 4.6. rHsGal-1 treatment modulates membrane repair and inflammation in patientderived, dysferlin deficient cells. A. Representative images of laser injury assay performed on
patient-derived, dysferlin deficient cells. Images were taken at 0, 30, 60, and 90 s post injury. B.
Quantification of laser injury on patient derived, dysferlin deficient cells. Cells were treated with
either 0.11 μM rHsGal-1 or PBS (NT) C. Representative images of dysferlin deficient human
myotubes cultured and immunostained with p65 (green), Phalloidin (red), and DAPI (blue). D.
Quantification of immunofluorescence of p65 relative to DAPI control in dysferlin deficient human
myotubes treated with either 0.11 μM rHsGal-1 or NT. E. Quantification of Western blot for p65 βtubulin control done on dysferlin deficient human myotubes NT or treated with 0.11 μM rHsGal-1.
F. Western blot image for p65 and β-tubulin from dysferlin deficient human myotubes. *<0.05,
**<0.01, ***<0.001, ****<0.0001 NT vs. rHsGal-1. Bars are represented as SEM.
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There is a direct relationship between mouse muscle health with cage exploration and
rearing 225. Both of these indices were significantly improved in mice treated with rHsGal-1. We
suspect this increase in movement is due to the ability of rHsGal-1 to reduce inflammation and
promote muscle membrane repair. Mechanically, we believe the rHsGal-1 is working to facilitate
the formation of the membrane patch, an integral component in membrane repair. Together, our
results from the one-week and one-month experiments demonstrate that rHsGal-1 affects muscle
membrane mechanically through Gal-1 localization to the membrane and biologically through
inflammatory signaling. 42 More investigation is needed to show the proteins that rHsGal-1
interacts with as it mediates membrane repair. Regardless of mechanism, the treatment with
rHsGal-1 in BLA/J mice suggests an improvement in muscle health as evidenced in the laser
injury, CLAMS cages, biochemical, and histological assays.
Furthermore, rHsGal-1 showed the same therapeutic potential when administered to
patient-derived dysferlin-deficient cells (Figure 4.6). rHsGal-1 shows promise at diminishing the
symptoms of LGMD2B in two areas of pathology: inflammation and muscle membrane repair.
This two-pronged mechanism would be extremely useful as a therapeutic and may stem from the
ability of rHsGal-1 to function as either a monomer or a dimer. The dimer form of rHsGal-1 is
clearly more beneficial in assisting in the membrane repair process, while the monomeric version
helps to reduce the markers of inflammation. Although more testing is required, these two
parallel processes position rHsGal-1 as a highly effective therapeutic against LGMD2B.
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4.4 Discussion
Mutations of the dysferlin gene lead to impaired sarcolemma repair with limited
treatment options. 77, 203 In addition to defective membrane repair, muscles that lack functional
dysferlin exhibit chronic muscle inflammation and abnormal lipid metabolism. 132, 226, 227 Steroid,
stem cell, or gene replacement therapies to restore functionality of dysferlin are under
investigation. 66, 228, 229 However, these treatments are still far from clinical application. Our
previous study showed that in vitro and ex vivo rHsGal-1 treatment improves myogenesis
and membrane repair in dysferlin- deficient models. 42 However, the mechanism behind this
improvement is not clear. The multiplicative roles of Gal-1 align with our current results.
Here, we provide evidence that rHsGal-1 acts via two discrete mechanisms: restoration of
membrane integrity and decrease of inflammatory response in LGMD2B models.
We presented data uncovering the biological activity of different types of Gal-1 in
membrane repair and inflammation by testing multiple forms of Gal-1 in various oxidation
states. An effective therapeutic for LGMD2B patients should address both muscle repair and
chronic inflammation in order to reverse pathophysiology. Both rHsGal-1 and reduced dGal-1
effectively improved membrane repair in vitro and ex vivo (Figure 4.1E, 4.1F, & 4.1G).
Because monomeric and oxidized dGal-1 treatments were ineffective, the reduced dimeric form
of Gal-1 is likely responsible for the bulk enhancements in membrane repair in the rHsGal-1
treatment. This aligns with previous studies which state that the CRD domain of Gal-1 is
inactivated via oxidation, and that the CRD is necessary for membrane repair. 42, 206 The fact that
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rHsGal-1 and oxidized forms of mGal-1 and dGal-1 both reduced levels of p65 illustrates
different niches for the various forms of Gal-1, with oxidized Gal-1 playing a larger role in
inflammatory signaling. The dynamic nature of rHsGal-1 allows it to excel at both signaling and
membrane repair.
We posit that micro-cellular environmental changes of the various monomer/dimer and
redox states of rHsGal-1 are responsible for decreased LGMD2B manifestations. Because of the
monomer/dimer modulation, we infer that Gal-1 assists in membrane repair processes as a dimer
and simultaneously decreases inflammation as a monomer in our A/J-/-, Bla/J, and patient
dysferlin-deficient models. Further studies on rHsGal-1 cellular surface and intracellular
interactome are needed to deduce additional information on the pathways and mechanisms by
which Gal-1 decreases inflammation.
Abnormal expression in the NF-κB pathway causes detrimental effects that accompany
inflammation. 230 In accordance with previous studies, we gathered indirect evidence that Gal-1
is associated with downregulated NF-κB activity. 42 For example, phosphorylated p65, which is
required for NF-κB relocation to the nucleus, was significantly downregulated in vitro and in
vivo. 231 While encouraging, reduction of P-p65 and other elements of the NF-κB pathway do not
always correlate with changes in nuclear NF-κB activity and changes in genes being transcribed.
However, based on the data we have, we conclude that NF-κB pathway activation is likely also
downregulated, although more research including promotor studies are needed to confirm this
directly. The NF-κB pathway is activated by two different signaling cascades, the canonical and
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the non-canonical pathways, each with unique signaling and biological functions. 232, 233 This
study demonstrates that rHsGal-1 is affecting the NF-κB response through the canonical
pathway, TAK-1 or the receptor for TAK-1. Since dysregulation of the non-canonical pathway is
associated with lymphoid malignancies and autoimmune diseases, it is beneficial that rHsGal-1
is not eliciting this response.
NF-κB activation triggers gene expression for a broad range of pro-inflammatory
cytokines, chemokines, and adhesion molecules; therefore, it is unsurprising that Gal-1 treatment
affects all of these. The cytokines significantly upregulated with treatment (IL-4, CXCL1,
MCP1, and TIMP-2) play a unique role in the cell and may further explain the therapeutic effect
of exogenous Gal-1 treatment. IL-4 is a well-studied anti-inflammatory cytokine involved in
myogenesis and tissue repair. 197, 223, 234 In a recently published study, a direct treatment with IL4 improved muscle differentiation. 221, 235 This is most interesting since Gal-1 treatment in mouse
and human model of both Duchenne and LGMD2B both increase muscle differentiation. It
should be noted that many cytokines and chemokines have alternative promotor elements that
may have consequences unrelated to the NF-κB pathway which require further investigation.
Thus, it is reasonable to conclude that Gal-1 upregulation of Il-4 might drive these changes in
differentiation.
Additionally, IL-4 is involved in changing the polarization of macrophages from M1
to M2. 236-238 M1 macrophages are upregulated in dysferlin deficient muscle, which has been
shown to contribute to muscle damage. 239 It is possible that rHsGal-1 might polarize
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macrophages in Bla/J mice through the upregulation of IL-4. This signaling may be the avenue
that ultimately leads to greater muscle health. Therefore, upregulation of IL-4 in response to
rHsGal-1 treatment may reduce the negative effects of chronic inflammation in LGMD2B and
lead to greater muscle health (Figure 4.5). The CXCL1, MCP-1, and TIMP-2 cytokines are
involved in tissue regeneration, wound healing, and ECM regulation respectively, all of which
can contribute to overall muscle health in vivo. 240-242 We suspect that these cytokines contribute
toward the therapeutic action of Gal-1, but more investigation is necessary.
Previous researchers provide evidence that activation of NF-κB can increase Gal-1
transcription. 78 Thus, seeing an increase in Gal-1 transcript would be expected when NF-κB is
activated. Gal-1 is upregulated in diseases with chronic injury such as other types of muscular
dystrophy. 94 Specifically, in LGMD2B, Gal-1 transcript levels are 3.8 time higher in patient
tissue over non-diseased tissue. 243 Although the levels of endogenous Gal-1 in Bla/J mice is
unknown, WT and diseased cell models showed similar transcript levels of Gal-1 as shown in
our previous study. However, the mRNA levels were upregulated 2-fold with the Gal-1
treatment.42 Even though the impact of adding exogenous Gal-1 in WT mice has not been
defined, studies have shown that IP injection of Gal-1 to treat inflammation in other diseased
tissues leads to upregulated endogenous Gal-1 over a period of 24 hours. 244 Our results show
that, along with negative NF-κB modulation, there is an increase in endogenous Gal-1
transcription due to our exogenous rHsGal-1 treatment compared to PBS treated Bla/J mice.
These data suggest a novel self-upregulation loop where Gal-1 positively modulates its own
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expression. This positive feedback loop could be related to the role of Gal-1 as an alternative
pre-mRNA splicing factor, other unknown nuclear interactions or yet to be defined signaling
pathway. 81 This phenomenon deserves further consideration and experiments to clarify the
mechanism of how Gal-1 is able to self-upregulate.
The results obtained during our one-week dose response experiment show that there
is a 6-fold therapeutic range at which rHsGal-1 was effective. The effective concentration seems
to peak at 2.7 mg/kg rHsGal-1 every seven days. Although the following doses did not provide
benefit: 0.27 mg/kg D0, D7; 0.54 mg/kg D0, D7; and 13.5 mg/kg D0, D7, they also did not result
in worsening membrane repair. This shows a safety profile of doses between 0.54-13.5mg/kg in
Bla/J mice. This 25-fold safe dosing range, along with pharmacokinetic studies, shows that the
treatment of rHsGal-1 takes approximately 12 hours to return to pre-dosing levels of Gal-1,
indicating that this biologic may be a safe option for human patients.
Functional, histological, and biochemical experiments in our one-month study provide
additional evidence of therapeutic benefit with rHsGal-1 treatment. Decreased inflammation may
be a fundamental reason for observed increased muscle integrity in treated animals, as
inflammation has been shown to play a large role in the pathological symptoms of LGMD2B. 132,
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A primary histological marker for LGMD2B is lipid deposition in affected muscles. This fatty

infiltration has been linked to the presence of inflammatory markers. 246 Decreased perilipin with
rHsGal-1 treatment demonstrates a decrease in fat deposition within Bla/J myofibers.
Biologically, rHsGal-1 decreases inflammation through the NF-κB pathway and upregulates
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cytokines with anti-inflammatory and regenerative effects. We hypothesize that the decrease in
fat deposition is due to decreased activation of the canonical NF-κB pathway as a result of
treatment.
There is a direct relationship between mouse muscle health with cage exploration and
rearing 225. Both of these indices were significantly improved in mice treated with rHsGal-1. We
suspect this increase in movement is due to the ability of rHsGal-1 to reduce inflammation and
promote muscle membrane repair. We believe the rHsGal-1 works mechanically to facilitate the
formation of the membrane patch, an integral component in membrane repair. Together, our
results from the one-week and one-month experiments demonstrate that rHsGal-1 affects muscle
membrane mechanically by Gal-1 localization to the membrane and biologically through
inflammatory signaling 42. More investigation is needed to show the proteins that rHsGal-1
interacts with as it mediates membrane repair. Regardless of mechanism, the treatment with
rHsGal-1 in Bla/J mice suggests an improvement in muscle health as evidenced by the CLAMS
cages, the laser injury, biochemical, and histological assays.
Furthermore, rHsGal-1 showed the same therapeutic potential when administered to
patient-derived dysferlin-deficient cells (Figure 6). rHsGal-1 shows promise at diminishing the
symptoms of LGMD2B in two areas of pathology: inflammation and muscle membrane repair.
This two-pronged mechanism would be extremely useful as a therapeutic and may stem from the
ability of rHsGal-1 to function as either a monomer or a dimer. The dimer form of rHsGal-1 is
clearly more beneficial in assisting in the membrane repair process, while the monomeric version
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helps to reduce the markers of inflammation. Although more testing is required, these two
parallel processes position rHsGal-1 as a highly effective therapeutic against LGMD2B.

4.5 Patents
The University of Nevada-Reno has been issued a patent in the U.S. (# US20130065242
A1) and Australia (# 45557BOA/VPB) for, “Methods for diagnosing, prognosing and treating
muscular dystrophy”. PMVR is an inventor on these patents. Strykagen currently holds the
license for this technology.
Brigham Young University has a pending patent for “Galectin-1 immunomodulation and
myogenic improvements in muscle diseases and autoimmune disorders.” (#U.S. Pat. No.
62/161,027. PCT/US2021/026232). PMVR and MLVZ are the inventors of this patent. This does
not alter our adherence to MDPI-Cells policies on sharing data and materials.
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4.6 Supplementary Materials

4.6.1 Supplemental Figure S4.1

S4.1 Fig. Crystal structure and model of various forms of Galectin-1. A-B. Crystal structure and model of
recombinant Human Galectin-1 (rHsGal-1) bound to generic β-galactoside ligand (Modeled from PDB 1GZW). CD. Crystal Structure and model of Wild Type Galectin-1(WT Gal-1) bound to generic β-galactoside ligand (PDB
1GZW). E-F. Crystal Structure and model of monomeric Galectin-1(mGal-1) bound to generic β-galactoside ligand
(PDB 1GZW). G-H. Crystal Structure and model of dimeric Galectin-1(dGal-1) bound to generic β-galactoside
ligand (PDB 1GZ.
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4.6.2 Supplemental Figure S4.2

S4.2 Fig. Structure and Purification of different types of Gal-1. A. Crystal Structure of Wild Type Galectin-1 (WT
Gal-1) bound to generic β-galactoside ligand (PDB 1GZW) and western blot image of WT Gal-1at decreased
dosage. B. Model of recombinant Human Galectin-1 (rHsGal-1) bound to generic β-galactoside ligand (Modeled
from PDB 1GZW) and western blot image of rHsGal-1 at decreased dosage. C. Model of alkylated rHsGal-1 bound
to generic β-galactoside ligand (Modeled from PDB 1GZW) and western blot image of alkylated rHsGal-1 at
decreased dosage. D. Representative structure of the fixed monomeric form of Gal-1 and western blot image with
serial dilution for verification of proper construction. E. Representative structure of the fixed dimeric form of Gal-1
and western blot image with serial dilution for verification of proper construction.

136

4.6.3 Supplemental Figure S4.3

S4.3 Fig. rHsGal-1 Dose optimization in explant and in vivo Bla/J myofibers. A. Quantified laser injury assay on
explant mouse muscles from BLA/J mice treated with 0.011 μM rHsGal-1 (0.1X), 0.11 μM rHsGal-1 (1X), 1.1 μM
rHsGal-1 (10X) compared to PBS treated control. B. Quantified laser injury assay on mouse muscles from BLA/J
mice treated in vivo 27 mg/kg rHsGal-1 (10X) compared to PBS treated control. Muscles were taken and injured 24
hours after treatment. C. Quantified laser injury assay on mouse muscles from BLA/J mice treated in vivo 2.7 mg/kg
rHsGal-1 (1X) compared to PBS treated control. Muscles were taken and injured 48 hours after treatment. D.
Quantified laser injury assay on mouse muscles from BLA/J mice treated in vivo 2.7 mg/kg rHsGal-1 (1X) compared
to PBS treated control. Muscles were taken and injured 2 hours after treatment. E. Timeline for experiments shown
in A-E. Black dot = treatment. Yellow bolt = injury. Values were measured by Tukey’s multiple comparison test and
indicated by: ****p< 0.0001, ***p<0.001, **p<0.01, and *p<0.05 between control and rHsGal-1 treated mice.
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4.6.4 Supplemental Figure S4.4

S4.4 Fig. 2.7 mg/kg is the best dose of rHsGal-1 improving membrane repair in ex-plant and in vivo Bla/J
myofibers. A. Quantified laser injury assay on BLA/J mouse muscles treated in vivo with 27 mg/kg rHsGal-1
compared to PBS treated control. Mice were treated three times in 7 days and muscles were taken on the seventh
day to be injured and imaged. B. Quantified laser injury assay on mouse muscles from BLA/J mice treated in vivo
2.7 mg/kg rHsGal-1 compared to PBS treated control. Mice were treated on day 0 and day 7. Muscles were taken
and injured 7 days after first treatment. C. Quantified laser injury assay on mouse muscles from BLA/J mice treated
in vivo 0.27 mg/kg rHsGal-1 compared to PBS treated control. Mice were treated on day 0 and day 7. Muscles were
taken and injured 7 days after first treatment. D. Quantified laser injury assay on mouse muscles from BLA/J mice
treated in vivo 2.7 mg/kg rHsGal-1 (1X) compared to PBS treated control. One rHsGal-1 and one PBS treated
mouse were treated on days 0 and 7, while the other rHsGal-1 and PBS treated mice were treated on days 0 and 5.
Muscles were taken and injured 7 days after first treatment. *=PBS vs 2.7 mg/kg rHsGal-1 (D0, D7); #=PBS vs 2.7
mg/kg rHsGal-1 (D0, D5). E Quantified laser injury assay on mouse muscles from BLA/J mice treated in vivo with
0.27 mg/kg rHsGal-1 every other day, 0.54 mg/kg rHsGal-1 on days 0 and 7, 2.7 mg/kg rHsGal-1 on days 0 and 7,
and 8.1 mg/kg rHsGal-1 on days 0 and 7 compared to PBS treated control. All muscles were taken and injured 7
days after first treatment. #=0.54 mg/kg vs 2.7mg/kg; *=PBS vs 2.7 mg/kg; %=PBS vs 0.27 mg/kg; $=PBS vs 8.1
mg/kg. F. Quantified laser injury assay on mouse muscles from BLA/J mice treated in vivo with 1.35 mg/kg rHsGal1, 2.7 mg/kg rHsGal-1, and 5.4 mg/kg rHsGal-1 compared to PBS treated control. Mice were treated on days 0 and
7. Muscles were taken 7 days after first treatment. (G). Quantified laser injury assay on mouse muscles from BLA/J
mice treated in vivo with 1.35 mg/kg rHsGal-1, 2.7 mg/kg rHsGal-1, and 13.5 mg/kg rHsGal-1. Mice were treated
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on days 0 and 7. Muscles were taken 7 days after first treatment. (H). Quantified laser injury assay on mouse
muscles from BLA/J mice treated in vivo with 2.7 mg/kg rHsGal-1 or PBS control. Mice were treated on day 0 and
7, day 0 only, or day 7 only. *=PBS vs rHsGal-1 D0,7; #=PBS vs rHsGal-1 D7 only; %= rHsGal-1 D0,7 vs
rHsGal-1 D0 only; &=PBS vs rHsGal-1 D0 only. Values for all graphs were measured by Tukey’s multiple
comparison test and indicated except noted by: ****p< 0.0001, ***p<0.001, **p<0.01, and *p<0.05 between
control and rHsGal-1 treated mice.

4.6.5 Supplemental Figure S4.5

S4.5 Fig. Quantification of percentage of twitching myotubes. ****p< 0.0001 between NT and rHsGal-1
treated myotubes.
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CHAPTER 5: FUTURE DIRECTIONS AND ACCOMPLISHMENTS

5.1

Future Directions
Dysferlinopathies lead to progressive muscle disease due to impaired repair of the

membrane.44 Currently, no etiological treatment is available for patients affected with
dysferlinopathies. Recent data examined the role of some proteins involved in membrane repair,
but the detailed mechanism by which dysferlin contributes to membrane repair is still elusive.127,
141, 143, 247

Our data provide strong evidence that after 48h treatment, low doses of rHsGal-1

increase myogenic potential in dysferlin-deficient myoblasts. A deeper investigation of the
mechanism by which rHsGal-1 facilitates expression of myogenic markers will provide valuable
insights in muscle regeneration.
The finding that rHsGal-1 improves membrane repair in in vitro and in vivo models of
LGMD2B, independent of Ca2+, and dependent on the rHsGal-1 CRD, is completely novel.
These results have significant therapeutic implications because it implies that stabilization of the
membrane could be through structural interaction of the CRD domain of Gal-1. Although the
exact underlying cellular and molecular mechanism by which rHsGal-1 helps to repair the
membrane is not well defined, our data from chapter 2 and 4 demonstrates clearly that rHsGal-1
robustly improves membrane repair capacity in LGMD2B models and begins to unravel the
mechanism. Therefore, future studies related to the interactions between rHsGal-1 and other
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proteins, or lipid modulation, will be critical to better understand the regulation of this protein in
membrane repair.
Additionally, our data indicate that rHsGal-1 accumulates and may form patches at the
membrane lesions. However, the mechanism behind patch formation at the site of the injury is
not clear. Preliminary data shows that blocking vesicle transport pathways inhibits the effects of
rHsGal-1 in membrane repair in in vitro experiments. A comprehensive vesicle transport assay
will provide evidence whether endo- or exocytosis of rHsGal-1 vesicles contribute to repair the
membrane in dysferlin-deficient cells or muscle fibers. A/J-/- NT or 0.11μM rHsGal-1 treated
myotubes in presence or absence of MITMAB (a dynamin I and dynamin II, endocytosis
inhibitor) and Endosidin2 (target the EXO70 subunit to inhibit exocytosis) were subjected to a
laser injury. The results showed that myotubes treated with endo- or exocytosis inhibitors were
not able to repair the membrane. It suggests that both endo- and exocytosis processes contribute
to membrane repair (Figure 5.1 &5.2).
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Figure 5.1. Endocytosis in membrane repair. Quantification of the total change of fluorescence in A/J-/myotubes. * NT vs 0.11μM rHsGal-1. # 0.11μM rHsGal-1 vs 0.11μM rHsGal-1+ 3μM MITMAB. p values
were measured by Tukey’s multiple comparison test and indicated by * p< 0.05, ** p< 0.01, and *** p<
0.001. Error bars represent SEM. n= 15 myotubes per condition.
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Figure 5.2. Exocytosis in membrane repair. Quantification of the total change of fluorescence in A/J-/- myotubes.
*= NT +DMSO vs 0.11μM rHsGal-1+DMSO. #= NT+DMSO vs 0.11μM rHsGal-1+DMSO+ES2. $= NT+DMSO
+ES2 vs 0.11μM rHsGal-1+DMSO. &= 0.11μM rHsGal-1+DMSO vs 0.11μM rHsGal-1+DMSO+ES2. p values
were measured by Tukey’s multiple comparison test and indicated by *p< 0.05, **p< 0.01, and ***p< 0.001. Error
bars represent SEM. n= 15 myotubes per condition.
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Patients with dysferlinopathies show an increased amount of resident muscle
macrophages.239 Our hypothesis is that if Gal-1 could change the resident macrophage
population towards a cyto-regenerative M2 phenotype, it could improve muscle regeneration in
dysferlin-deficient patients. To test our hypothesis, we used Raw264.7 macrophage cells as a
model to detect rHsGal-1 mediates macrophage polarization. Raw264.7 were grown in media
containing either 0.11µM rHsGal-1, 100ng/ml INF-γ (promotes M1), or 20ng/ml IL-4 (promotes
M2). Preliminary results showed that Raw264.7 macrophages treated either with rHsGal-1 or IL4 expressed similar fluorescence of CD206 (M2). (Fig. 5.3). Then, we decided to conduct a
short-term 1-week in vivo 2.7 mg/kg rHsGal-1 treatment in mice (n=3 per codition). Peritoneal
macrophages were isolated from 36-50 week-old Bla/J mice using techniques previously
described in Ray and Dittel.248 Flow cytometry data shows that in rHsGal-1 treated mice
receiving a weekly dose of 2.7 mg/kg, 35.6% of macrophages expressed CD206 (M2) and 18.2%
expressed CD86 (M1) whereas PBS treated mice showed 3.4% of macrophages expressed
CD206 (M2) and 62.7% expressed CD86 (M1) (Fig 5.4).
This suggests that rHsGal-1 could effectively polarize resident macrophages to an M2
phenotype in LGMD2B in vivo models. We next conducted a 1-month in vivo 2.7 mg/kg rHsGal1 treatment in mice (n=3 per condition). Flow cytometry data shows that in rHsGal-1 treated
mice receiving a weekly dose of 2.7 mg/kg, 15.0 % of macrophages expressed CD206 (M2) and
2.26 % expressed CD86 (M1) whereas PBS treated mice showed 3.25% of macrophages
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expressed CD206 and 30.6% expressed CD86 (M1) (Fig 5.5). This indicates that after 1-month,
2.7mg/kg rHsGal-1 weekly treatment decreases M1 population and keeps the M2 phenotype
constant in LGMD2B in vivo models (Fig 5.5). Overall, these results suggest that in vitro and in
vivo treatment with rHsGal-1 in dysferlin-null mice resulted in decreased inflammatory
macrophages (M1) and increased anti-inflammatory macrophages (M2).

Figure 5.3. rHsGal-1 polarizes Raw264.7 macrophages from M1 M2. A. Immunofluorescence in pictorial
representation of Raw264.7 macrophages NT or treated with rsGal-1, IL-4, or INF-γ stained with CD86 (Red),
and CD206 (Green). B. Zoom of A.

147

A 1-week treatment with Galectin-1 in dysferlin-null mice resulted in a decrease in
inflammatory macrophages (M1) and an increase in anti-inflammatory macrophages (M2)
(Fig.5.4). After a one-month treatment with Galectin-1, M1 macrophages remained reduced,
although the M2 population also returned to saline-treated levels (Fig. 5.5). The levels of p50
and p65 in muscles were also reduced during the 1-month treatment (Fig. 4.4E). These results
indicate that Galectin-1 treatment can improve membrane repair capability and attenuate some of
the inflammatory response in in vivo as well as in vitro, although the long-term response and
mechanism of macrophage polarization remains to be tested.

Figure 5.4. Peritoneal macrophage polarization in a 1-week in vivo rHsGal-1 treatment in BLA/J mice. A.
Representative image of fluorescent data comparing C86 APC-A (M1) and CD206 PE (M2) populations in Bla/J
mice PBS treated. B. Representative image of fluorescent data comparing C86 APC-A (M1) and CD206 PE (M2)
populations in 2.7mg/kg rHsGal-1 treated BLA/J mice.
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Figure 5.5. Peritoneal macrophage polarization in a 1-month in vivo rHsGal-1 treatment in BLA/J mice. A.
Representative image of fluorescent data comparing C86 APC-A (M1) and CD206 PE (M2) populations in Bla/J
mice PBS treated. B. Representative image of fluorescent data comparing C86 APC-A (M1) and CD206 PE (M2)
populations in 2.7mg/kg rHsGal-1 1x/week treated BLA/J mice.

Further experimentation is required to assert Gal-1 responsibility in this M1 or M2 shift.
Mass spectrometry and Gal-1 fusion BioID proteins will help to evaluate macrophage and NFκB markers such as iNOS (M1) and Arg (M2) to determine how rHsGal-1 is performing these
modifications in dysferlin-deficient models. From chapter 4, we observed Gal-1 lowering
inflammation, but the mechanism of action as to how this occurs is still unknown. The reduced
expression levels in TAK1, and the NF-ᴋB subunits, p50 and p65 suggest that NF-ᴋB inhibition
is occurring upstream. This suggests that the examination of some of the many NF-ᴋB receptors,
especially TNFR, would provide additional insight into these results. The TNFR receptor is
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involved in N-glycosylation reactions.249 Since it has been shown that Gal-1 can bind to Nglycan moieties on TNFR, it implies that Gal-1 binding could be inhibited through either TNFR
or TNFα interactions. In conclusion, this data strongly indicates that rHsGal-1 has potential to
minimize the problem of chronic inflammation found in LGMD2B and is therefore a strong
overall candidate for the treatment of LGMD2B and possibly other chronic inflammatory
diseases.

5.2

Summary of the Novel Results Published in This Dissertation
In this work, we examined the role of Gal-1 to better understand the membrane repair

process and inflammatory response to develops a novel therapy to improves function and quality
of life in LGMD2B patients.
In our study we have provided novel data showing that:
1. rHsGal-1 increases myogenic potential in A/J-/- myotubes.
2. rHsGal-1 treatment increases levels of fusion index and myotube maturity.
3. Treatment with rHsGal-1 restores membrane repair capacity in dysferlin deficient
myotubes.
4. Increased rHsGal-1-mediated repair capacity is dependent on the CRD of rHsGal-1 and
independent of Ca2+ in both dysferlin-deficient and non-diseased models.
5. Ex-vivo rHsGal-1 treatment increases membrane repair capacity in dysferlin deficient
myofibers.
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6. rHsGal-1 localizes at the site of injury and sites of cellular fusion in dysferlin-deficient
myotubes.
7. Dimeric rHsGal-1(dGal-1) was successfully designed, produced, and purified.
8. rHsGal-1 and WTGal-1 are indistinguishable in repair membrane of A/J-/- myotubes.
9. Alkylated and reduced rHsGal-1 have the same performance in membrane repair.
10. rHsGal-1 is the most biologically efficient type of Gal-1 for improving sarcolemma repair
in A/J-/- myotubes and BLA/J myofibers.
11. Weekly treatment 2.7mg/kg rHsGal-1 is the optimal dosage for increasing membrane
repair capacity in dysferlin-deficient mice.
12. In vitro and in vivo treatment of rHsGal-1 modulates inflammatory response through the
NFκ-B pathway
13. 0.11μM rHsGal-1 48-h treatment improves sarcolemma repair in patient-derived
dysferlin-deficient cells.
14. 0.11μM rHsGal-1 48-h treatment decreases inflammatory response in patient-derived
dysferlin-deficient cells.
15. rHsGal-1 could effectively polarize resident macrophages to an M2 phenotype in
dysferlin-deficient mice.
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5.3

Graphical Abstracts

Figure 5.6. Gal-1 role in NF-ᴋB inflammation and Macrophage polarization. Graphical abstract of the
purposed mechanism how Galectin-1 reduces Nf-ᴋB inflammation and promotes M2 macrophage phenotype.
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Figure 5.7. Cellular View of the Proposed Mechanism for Pathogenesis of Dysferlinopathies.
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Outcomes

Figure 5.8. Outcomes of rHsGal-1 treatment in Dysf-/- models
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